# Table of Contents

Schedule at a Glance ........................................... 1-3  
Officers and Committee Lists ................................. 4  
Supporter Recognition ........................................ 5  
Research and Education Fund ................................. 6-7  
George E. Slotkin Lecturers ................................. 8  
Guest Speakers .............................................. 9–13  
Publication of Abstracts ....................................... 14  
Program .................................................... 15–25  
Nursing Program ............................................... 26  
Social Event Info: Dine Around ......................... 27–28  
Social Event Info: Tours ..................................... 29–30  
Social Event Info: Events ................................... 31–33  
Exhibitor Listing (alpha) .............................. 34–38  
Exhibitor Listing (by Booth Number) ............... 39  
Disclosure Information ................................... 40–41  
CME Form ................................................ 42
CONTINUING MEDICAL EDUCATION

Accreditation
The American Urological Association Education and Research, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Urological Association Education and Research, Inc. takes responsibility for the content, quality and scientific integrity of this CME activity.

CME Credits
The American Urological Association Education and Research, Inc. designates this educational activity for a maximum of 16.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Statement
As a sponsor accredited by the ACCME, the American Urological Association Education and Research, Inc. must insure balance, independence, objectivity and scientific rigor in all its sponsored activities. All faculty participating in a CME accredited sponsored program are expected to disclose to the audience any significant financial interest or other relationships with commercial supporters. The intent of this disclosure is not to prevent a speaker with a significant financial interest or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. The AUA manages and resolves the conflicts of interest with commercial support in advance of the program and uses a variety of mechanisms to ensure balance and fairness in the program presentations. It remains for the audience to determine if the speaker’s interests or relationships may influence the presentation with regard to exposition or conclusion.

Educational Goals and Objectives
The Annual Meeting of the Northeastern Section of the American Urological Association, Inc. is designed to provide a forum for communicating to the members and guest physicians the developing state of the art of science of urological techniques, evaluations and procedures. The program will include original papers presenting new information addressing pertinent clinical topics. Panel discussion and point-counterpoint sessions on topical issues allow for participants to openly discuss procedure and techniques. Participants will have the opportunity to discuss presentations and address questions to authors. At the completion of the Annual Meeting, participants should be able to apply this new information on research and techniques in their daily practice.

Unlabeled or Unapproved Use of Drugs or Devices
In accordance with the Essential Areas and Policies relating to commercial support, the audience is advised that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer
The opinions and recommendations expressed by faculty/authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the American Urological Association Education and Research, Inc.
<table>
<thead>
<tr>
<th>Time/Room</th>
<th>Confederation 1</th>
<th>Confederation 2,3</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>Live Surgery Telecast 1st Case from London, Ontario, John D. Denstedt, M.D.</td>
<td></td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Intuitive Robotics Video Session</td>
<td></td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Live Surgery Telecast 2nd Case from London, Ontario, John D. Denstedt, M.D.</td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Exhibit Hall Sneak Peak Luncheon</td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>State-of-the-art Lectures 1 - 3:00</td>
<td></td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 p.m.</td>
<td>Coffee Break</td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>State-of-the-art Lectures 3:30 - 5:30</td>
<td></td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td></td>
<td>Exhibit Hall Opening Welcome Reception (Platinum Supporters Plaques presented)</td>
</tr>
<tr>
<td>6:00 p.m.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00 p.m.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7:00 a.m. - 4:00 p.m. — Registration open in 4th floor foyer
2:00 - 4:30 a.m. — Hospitality Room, New Brunswick
7:30 - 10:00 p.m. — Dine-Around
<table>
<thead>
<tr>
<th>Time/Room</th>
<th>Confederation 1</th>
<th>Confederation 2,3</th>
<th>Province 1</th>
<th>Province 2</th>
<th>Les Saisons (Nursing Program)</th>
<th>British Columbia</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 a.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6:45-7:45 a.m. Residents Breakfast</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td>Podium Session 1 — Prostate Cancer (Papers 1 - 7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8:10 - 8:30 a.m. — Welcome</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>Guest Lecture: Lymph Node Dissection in GU Surgery, Michael Koch, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>8:30 - 9:55 a.m. — Interstitial Cystitis: Past, Present, and Future, Vicki Ratner, M.D.</td>
</tr>
<tr>
<td></td>
<td>Point-Counter-Point: Open vs. Robotic vs Laparoscopic Prostatectomy Drs. Joseph, Carrol, Moinzadeh</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderated Poster Session I — Prostate Cancer (P1-17)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10:00 - 10:15 a.m. - Break</td>
</tr>
<tr>
<td></td>
<td>View Posters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Podium Session II — Bladder Cancer (Papers 8-14)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Guest Lecture — Superficial Bladder Cancer, Leonard Gomella, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td>Visit Exhibit Hall/Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exhibit Hall Open (Lunch Served)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Lunch in Exhibit Hall</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 p.m.</td>
<td>Podium Session III — Pediatric Urology (Papers 15-22)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1:30 - 2:45 p.m. — GU Pathology (Why are they having a Pathologist talk?) Steve K. Landas, M.D.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 p.m.</td>
<td>Guest Lecture — Current Concepts in the Management of Posterior Urethral Valves, Curtis Sheldon, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2:45 - 3:15 p.m. — Visit Exhibits</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Podium Session IV — Prostate Cancer Recurrence/Biopsies (Papers 23-26)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 p.m.</td>
<td>Guest Lecture — Prostate Cancer, Peter Carroll, M.D.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4:30 - 5:15 p.m. — Strategic Retirement and Estate Planning Solutions, Joel M Blau, CFP (Spouses invited)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7:00 a.m. - 4:00 p.m. — Registration open in 4th floor foyer
8:30 a.m. - 4:00 p.m. — Hospitality Lounge, New Brunswick
6:00 - 10:00 p.m. — Fun Night, Canadian War Museum

<table>
<thead>
<tr>
<th>Events</th>
<th>Telecasts</th>
<th>Lectures</th>
<th>Podium Sessions</th>
<th>Breaks</th>
<th>Poster Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time/Room</td>
<td>Confederation 1</td>
<td>Confederation 2,3</td>
<td>Province 1</td>
<td>Province 2</td>
<td>Les Saisons (Nursing Program)</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------</td>
<td>-------------------</td>
<td>------------</td>
<td>------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>7:00 a.m.</td>
<td>Annual Business Meeting</td>
<td></td>
<td></td>
<td></td>
<td>6:30 - 8:00 a.m. Residents Breakfast — Nikhil Shah, M.D.</td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td>Podium Session V: Laparoscopy (Papers 27-34)</td>
<td></td>
<td></td>
<td></td>
<td>View Posters</td>
</tr>
<tr>
<td>8:00 a.m.</td>
<td>Visit Exhibit Hall</td>
<td></td>
<td></td>
<td></td>
<td>Female Sexual Dysfunction, Bashar Omarbasha, M.D.</td>
</tr>
<tr>
<td>9:00 a.m.</td>
<td>Slotkin Lecture — Computer Assisted Robotic Surgery (CARS): A Paradigm Shift After 2600 Cases, Mani Menon, M.D.</td>
<td></td>
<td></td>
<td>Poster Session IV — Other Cancer (P46-62)</td>
<td>New Paradigms in Treatment of BPH, Grannum R. Sant, M.D.</td>
</tr>
<tr>
<td>10:00 a.m.</td>
<td>Exhibit Hall Open</td>
<td></td>
<td></td>
<td></td>
<td>Break — Visit Exhibit Hall</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Guest Lecture — Surgical Management of Patients with Complex Nephrolithiasis, Dean Assimos, M.D.</td>
<td></td>
<td></td>
<td></td>
<td>Erectile Dysfunction — Current Evaluation and Management, Jonathan D. Block, M.D., Ph.D., M.B.A., PFPM</td>
</tr>
<tr>
<td>11:00 a.m.</td>
<td>Guest Lecture — Interstitial Cystitis — Update on Pathophysiology and Treatment, Grannum R. Sant, M.D.</td>
<td></td>
<td></td>
<td></td>
<td>Comparison of Current Treatment Strategies for Overactive Bladder, Urge Urinary Incontinence, and Female Stress Urinary Incontinence in Canada and the United States, Kevin Victor Power, M.D.</td>
</tr>
<tr>
<td>12:00 p.m.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>US-Canadian Socioeconomics Update, Allan B. Patrick, M.D.</td>
</tr>
<tr>
<td>7:00 p.m.</td>
<td>7:00 - 10:00 p.m. Presidents Reception and Banquet</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

6:15 - 9:00 a.m. — 5K Run, Rideau Canal (Registration @ 6:15 a.m.)
7:00 - 10:00 a.m. — Registration open on 4th floor foyer
8:30 - 11:30 a.m. — Hospitality Lounge, New Brunswick
1:00 - 5:30 p.m. — Golf Tournament, Château Cartier
1:30 - 4:30 p.m. — Tennis, Ottawa Athletic Club
NORTHEASTERN SECTION
BOARD OF DIRECTORS 2005-2006

President
Gabriel P. Haas, M.D.
Syracuse, NY

President-Elect/Secretary
Barry A. Kogan, M.D.
Albany, NY

Past President
John D. Denstedt, M.D.
London, Ontario

Secretary-Elect
Edward M. Messing, M.D.
Rochester, NY

Treasurer
Anne-Marie Houle, M.D.
Montreal, Quebec

Historian
Zahi Makhuli, M.D.
Syracuse, NY

Representatives
AUA Board of Directors
Datta G. Wagle, M.D.
Williamsville, NY

Canada
Allan B. Patrick, M.D.
Fredericton, New Brunswick

New York
Robert D. Mayer, M.D.
Rochester, NY

Pennsylvania
David A. Corral, M.D.
Pittsburgh, PA

At-Large
Michael E. Moran, M.D.
Albany, NY

At-Large
Ross G. MacMahon, M.D.
Winnipeg, Manitoba

2005-2006 NS-AUA Committee Listing

Arrangements Committee
Gabriel P. Haas, M.D., President
James W.L. Wilson, M.D.
John Eric Mahoney, M.D.

Awards Committee
John D. Denstedt, M.D., Chair
Gabriel P. Haas, M.D.
Ron Hrebinko, M.D.

Bylaws Committee
Barry A. Kogan, M.D., Chair
Gerald Benjamin Brock, M.D.
Stephen Edward Pautler, M.D.

Development Committee
J. Paul Whelan, M.D., Co-Chair
Datta G. Wagle, M.D., Co-Chair
Joseph M. Greco, M.D.
David B. Patrick, M.D.
Anne-Marie Houle, M.D.
Jean Volny Joseph, M.D.

George Slotkin Lecture Committee
Gabriel P. Haas, M.D., Chair
Barry A. Kogan, M.D.
John D. Denstedt, M.D.

Health Policy Committee
J. Paul Whelan, M.D., Chair
Joseph M. Greco, M.D.
Allan Beattay Patrick, M.D.
Ronald Paul Kaufman Jr., M.D.

Investment Committee
Anne-Marie Houle, M.D., Chair
Mark F. Bellinger, M.D.
Joseph L. Chin, M.D.
John D. Denstedt, M.D.

Judicial Committee
Joseph L. Chin, M.D., Chair
Mark F. Bellinger, M.D.
Kevin Pranikoff, M.D.

Nominating Committee
John D. Denstedt, M.D., Chair
Mark F. Bellinger, M.D.
Edward M. Messing, M.D.
Joel Byron Nelson, M.D.

Program Committee
Imad Salah Nsouli, M.D., Chair
Hassan Razvi, M.D.
David Anthony Corral, M.D.
Ronald P. Kaufman, M.D.
Jyoti J. Upadhyay, M.D.
D. Robert Siemens, M.D.

Scholarship Research Committee
Joel Byron Nelson, M.D., Chair
Sender Herschorn, M.D.
Erdal Erturk, M.D.
Badar Munir Mian, M.D.
The Northeastern Section of the American Urological Association would like to thank the following companies for their contribution and support of the 2006 Annual Meeting.

**Platinum Level Supporters**
($35,000 and above)
- Astellas Pharma US, Inc.
- Boehringer-Ingelheim Pharmaceuticals, Inc.
- Gyrus ACMI
- sanofi-aventis U.S. Inc.
- Pfizer Inc

**Gold Level Supporters**
($25,000 - $34,999)
- Bayer Oncology
- Watson Pharmaceuticals, Inc.

**Silver Level Supporters**
($15,000 – 24,999)
- Intuitive Surgical

**Additional Support**
- Coherent, Inc.
- Cook Canada
- Cook Urological
- GlaxoSmithKline
- Novartis
- sanofi-aventis Canada
NORTHEASTERN SECTION OF THE AMERICAN UROLOGICAL ASSOCIATION
DEVELOPMENT COMMITTEE

Datta G. Wagle, M.D., Co-Chair
Main Urology Associates
6645 Main Street
Williamsville, NY 14221
Phone: 716-631-0932
Fax: 716-631-2826
E-mail: dgwagle@aol.com

J. Paul Whelan, M.D., Co-Chair
McMaster Institute of Urology
50 Charlton Ave East
Hamilton, ON L8N 4A6
Canada
Phone: 905 521-6014
Fax: 905 528-3043
E-mail: whelanp@mcmaster.ca

Joseph M. Greco, M.D.
Windsong Medical Park
55 Spindrift Drive. #240
Williamsville, NY 14221
Phone: 716-631-9600
Fax: 716-631-9251

David B. Patrick, M.D.
1700 Third Street
Beaver, PA 15009
Phone: 724-775-
Fax: 724-775-4409

Anne-Marie Houle, M.D.
Hopital Sainte-Justine
3175 Cote-Sainte Catherine, A-4
Montreal PQ H 3T 1C5
Canada
Phone: 514-345-4931 (x 6811)
Fax: 514-345-4824
E-mail: anne-marie_houle@ssss.gouv.qc.ca

Jean Volny Joseph, M.D.
Box 656
601 Elmwood Ave
Rochester, NY 14642
Phone: 716 273-1688
Fax: 585 756-5457
E-mail: jean_joseph@urmc.rochester.edu
E-mail: jgreco@wnyurology.com

Administrative Offices
Mr. Drew Shifflet
Executive Administrator
1000 Corporate Boulevard
Linthicum, MD 21090
Phone: 410-689-4025
Fax: 410-689-3837
E-mail: dshifflet@auanet.org
Web: www.auanet.org/northeastern

NORTHEASTERN SECTION OF THE AUA 2006 ANNUAL MEETING
**Northeastern Section Research & Education Fund**

**Research and Education**

This fund was initiated in 1995 by Searle Canada and Searle USA. The purpose of this fund is to assure the membership of the NS-AUA continuing excellence in research and educational activity within our Section.

**Scholarship Program — Young Investigators Awards**

The NS-AUA Scholarship Program was established in 1998 to provide financial scholarships to support research and educational projects. The program currently offers up to two scholarship awards annually, of $30,000. These Young Investigator Awards provide financial assistance to a researcher in basic or clinical sciences related to urology, and to acquiring, developing or improving his or her knowledge and skills in a specific aspect of the specialty.

**Urology Residents and Fellows**

Beginning in 2002, the Section began offering support to 15 Urology Residency Programs in its geographical region by providing two (2) $1,000 stipends, per urology program, to help offset costs associated with sending residents/fellows to the Annual Meeting. This funding is sent directly to the teaching Institution. Contributions to the Research and Education Fund have also enabled the Section to provide special programming and events specifically tailored for urology residents.

Through the generosity of our Section members and corporate supporters, the Research and Education Fund continues to grow. We gratefully acknowledge and thank:

- Abbott Labs, LTD.
- Abbott - Canada
- Alza Pharmaceuticals
- Amgen and Praecis
- Astra Zeneca Pharmaceuticals, Inc. Canada
- Astra Zeneca Pharmaceuticals, Inc. USA
- Aventis
- Aventis Canada
- Aventis Oncology USA
- Bard Urological
- Bayer Corporation
- Berlex, Canada
- Boehringer Ingelheim — Canada
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Boston Scientific/Microvasive
- Bristol Meyer Squibb
- Cook Canada, Inc.
- Cook Urological
- Eli Lilly Corp.
- Glaxo-Smith Kline
- Gyrus ACMI
- Healthtronsics, Inc.
- Hoechst Marion Roussel Canada and USA
- Indevus Pharmaceuticals
- Janssen-Ortho
- Karl Storz Endoscopy – America, Inc. – USA and Canada
- Liebel-Flarsheim
- Lilly Icos
- Merck
- Merck & Co., Inc. – Urology Specialty Group
- Merck Frosst Canada
- Novartis Oncology
- Novartis Pharmaceuticals
- NS-AUA Members
- Ortho McNeil
- Pfizer Roerig
- Pfizer USA
- Pfizer Pharmaceuticals Group-Canada
- Pharmacia Corporation
- Pracaecis Pharmaceuticals, Inc.
- Proctor & Gamble Pharmaceuticals
- Sanofi-Synthelabo Canada
- Sanofi-Synthelabo, Inc.
- Schering Oncology/Biotech
- Tap Pharmaceuticals, Inc.
- Yamanouchi USA, Inc.

REGISTER ON LINE AT WWW.AUANET.ORG/NORTHEASTERN/
Excerpt from the Waterways chapter: “No history of the Northeastern Section is complete without a short biography of this indefatigable urologist. Dr. George E. Slotkin (1890-1971) (Fig. 10-13) was born in New York City but soon moved with his parents to Buffalo, NY, where he spent his professional career. We acknowledge him today as a founder, the first benefactor, and the first historian of the NS, but there is more to his story. If one were to hold up a mirror to the changing face of urology in the first half of the 20th century, it would be well reflected with an image of George E. Slotkin. A graduate of the University of Buffalo Medical School, Dr. Slotkin did postgraduate work at the New York City Post Graduate Hospital, the University of Vienna, and the University of Budapest. In 1918, he became a clinical professor of urology at the University of Buffalo. During the late 1940s, his clinical interest was tuberculosis of the urinary tract, which he treated with chalamagoric acid. Even though results of his work in this area remain inconclusive, other fruits of his career do not. Friends and colleagues of his time were fond of saying, ‘George Slotkin has three loves: urology, his wife Helene, and his Rolls Royce...not necessarily in that order!’ His early work, ‘Nephroptosis, a resurrected disease,’ was published in The Urologic and Cutaneous Review in 1938. His later work with E.A. Mercer, ‘Case of epispadias with a double urethra’, was published in The Journal of Urology® in 1953. Obviously, this change in his work reflects the change in urology from its early focus on genitourinary disease to its present focus as a surgical specialty. Dr. Slotkin was named Clinical Professor of Urology Emeritus in 1954 by the University of Buffalo Medical School and continued his private practice until 1964. After retirement, he continued to write, contributing a fascinating chapter about the history of the Northeastern Section to History of Urology. It is a priceless, logical record of carefully researched facts. His obituary notice implies that he may have been the first American invited to join the Canadian Urological Association. Dr. and Mrs. Slotkin did not have any children; his estate included a generous bequest to the Northeastern Section to provide funding for invited guest speakers at our annual meetings.” Meyer, Robert, M.D. and Margaret, “History of the Northeastern Section of the American Urological Association: Waterways.”


GEORGE E. SLOTKIN LECTURERS

1975 Prof. Willie L. M. Gregoir, Brussels, Belgium
1976 J. Engelbert Dunphy, M.D., San Francisco, California
1977 B. E. Christopher Nordin, M.D., Leeds, England
1978 Donald Smith, M.D., Piscataway, New Jersey
1979 J. Genest, M.D., Montreal, Quebec
1980 Joseph J. Kaufman, M.D., Los Angeles, California
1982 Donald S. Coffey, M.D., Baltimore, Maryland
1983 Martin I. Resnick, M.D., Cleveland, Ohio
1984 Willet F Whitmore, Jr., M.D., New York, New York
1985 Peter Scardino, M.D., Houston, Texas
1986 William Fair, M.D., New York, New York
1987 John Duckett, M.D., Philadelphia, Pennsylvania
1989 Robert Jeffer, M.D., Baltimore, Maryland
1990 Charles J. Devine, M.D., Norfolk, Virginia
1991 Thomas Stamey, M.D., Stanford, California
1993 Donald S. Coffey, M.D., Baltimore, Maryland
1994 Carl Olsson, M.D., Larchmont, New York
1995 Peter Scardino, M.D., Houston, Texas
1996 Bernard M. Churchill, M.D., Los Angeles, California
1997 Peter R. Carroll, M.D., San Francisco, California
1998 Joyce Lisa Tenover, M.D., Atlanta, Georgia
1999 Richard D. Williams, M.D., Iowa City, Iowa
2001 Alvaro Morales, M.D., Kingston, Ontario
2002 Edson Pontes, M.D., Detroit, Michigan
2003 Gerald L. Andriole, M.D., St. Louis, Missouri
2004 Mustafa Elhilali, M.D., Montreal, Quebec
2005 Margaret Sue Pearle, M.D., Dallas, Texas
2006 Mani Menon, M.D., Detroit, Michigan
2006 INVITED GUEST SPEAKERS

**Dean G. Assimos, M.D.**
Professor of Surgical Sciences
Department of Urology
Wake Forest University School of Medicine
Winston-Salem, NC

Dean Assimos is currently vice-chairman of the department of urology and professor of surgical sciences at the Wake Forest University School of Medicine in Winston-Salem, North Carolina. He received his B.S. from Purdue University in 1974 and his M.D. degree from Loyola Stritch School of Medicine in 1977. He completed his urology residency at Northwestern University in 1983. He was a clinical fellow in intra-renal surgery and stone disease at Wake Forest in 1983-1984 and subsequently was an AUA research fellow at the same institution from 1984-1986. His clinical interests are the medical and surgical management of patients with nephrolithiasis, and ureteral stricture disease. His basic science research focuses on the effects of dietary oxalate, endogenous oxalate synthesis and primary hyperoxaluria. He remains an active member of the AUA stone guidelines panel and currently serves on the AUA practice guidelines committee. He is a member of a number of organizations including the AUA, A.A.G.U.S., Endourology Society and the ROCK society. He serves on the editorial board of the Journal of Endourology, Urologic Research and Med Reviews in Urology.

**Joel M. Blau, CFP**
President
MEDIQUS Asset Advisors, Inc.
Chicago, IL

Joel M. Blau is President of MEDIQUS Asset Advisors, Inc. Prior to forming the firm, he was Vice President and Senior Financial Counselor for AMA Investment Advisers, L.P., and an affiliate of the American Medical Association. Mr. Blau has been responsible for the analysis and design of client’s financial plans. His areas of expertise include wealth preservation through estate tax planning, retirement, investment, and insurance planning. A CERTIFIED FINANCIAL PLANNER™ certificant, Mr. Blau earned his bachelor’s degree in business from Drake University, with a major in finance and a specialization in investments. His monthly financial articles are included in many state, county and national medical specialty society publications. He is a frequent public speaker and has given financial seminars for the American Medical Association as well as other professional medical associations, hospitals, and clinics. Mr. Blau has been included in "Who's Who In Finance and Industry" and "Who's Who of Emerging Leaders of America." He is a member of the Institute of Certified Financial Planner licensees and holds various securities and insurance licenses. Mr. Blau has co-authored Medical Practice Divorce: Successfully Managing a Medical Business Breakup (published by AMA Press) and most recently The Prescription for Financial Health: An Authoritative Guide for Physicians (published by Greenbranch Publishing).

**Gerald B. Brock, M.D.**
Professor, Department Of Surgery, Division Of Urology
University Of Western Ontario
London, Ontario
Canada

Dr Gerald Brock is currently Professor in the department of Surgery Division of Urology at the University of Western Ontario, Canada. He runs a large tertiary care erectile dysfunction and infertility clinic seeing over 1500 new consults annually. In addition he runs a productive basic research animal lab focusing on the effects of disease states on erectile physiology.

He is the author of more than 100 peer reviewed journal articles, 20 book chapters and has been awarded more than 20 research prizes for his work. He sits on the editorial board of several journals including the J. Sexual Medicine, J. Andrology and the Canadian J. Urology.

**Peter R. Carroll, M.D.**
Professor and Chair
Department of Urology
Ken and Donna Derr-Chevron Distinguished Professor
University of California, San Francisco

Dr. Peter Carroll received his undergraduate training at the University of California, Berkeley. After graduating with honors from Georgetown University School of Medicine, he came to UCSF for his general surgery training and urology residency. He completed a fellowship in Urologic Oncology at Memorial-Sloan Kettering Cancer Center before returning to join the faculty in the Department of Urology at UCSF.

Dr. Carroll organized the Urologic Oncology Service, one of the most active multidisciplinary programs at UCSF. In 1996, he assumed chairmanship of the UCSF Urology Department, consistently ranked as one of the top urology departments in the country by U.S. News and World Report. He holds the Ken and Donna Derr-Chevron Distinguished Professorship, and he has served as Surgeon-in-Chief of the UCSF Comprehensive Cancer Center since 2003.

Dr. Carroll has authored or co-authored over 323 publications. He is Associate Editor of the Journal of Urology® and plays a substantive role in other journals. He is an active member of numerous professional medical societies. He is currently principal or co-investigator of 7 peer-reviewed research grants, includ-
ing the UCSF Prostate Cancer SPORE, funded by the National Institutes of Health. His major professional interests are the study and management of urologic cancers, innovative methods of urinary tract reconstruction, and the impact of cancer detection and treatment on quality of life.

**Sam S. Chang, MD**
Associate Professor  
Department of Urologic Surgery  
Vanderbilt University School of Medicine  
Nashville, Tennessee

A graduate of Princeton University and Vanderbilt University, Dr. Chang completed his residency in urologic surgery at Vanderbilt and then completed a two year fellowship in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York, New York where he was Chief Fellow. His current position is Associate Professor of Urologic Surgery at Vanderbilt University. At Vanderbilt, he received a CaPCURE Young Investigator Award as well as being named as an AUA-EAU Academic Exchange Fellow.

A member of numerous organizations, currently he is a member of the AJA Foundation Prostate Advisory Board and the Vice-Chairman of the AUA Superficial Bladder Cancer Guidelines Panel. He also serves on the Executive Committee of the SUO and is the Chair of the Genito-Urinary Task Force for the AJCC in charge of cancer staging.

He has authored more than 100 publications with current research interests in diagnostic and treatment options for prostate, bladder and renal cancer.

**Gregg R. Eure, M.D.**
Assistant Professor of Urology  
Eastern Virginia Medical School  
Virginia Beach, VA

Gregg R. Eure, MD, FACS, is Assistant Professor of Urology at Eastern Virginia Medical School in Norfolk, Virginia. Dr. Eure also maintains a private urology practice with Devine-Tidewater Urology in Virginia Beach, a Division of Urology of Virginia. Dr. Eure received his medical degree from the Medical College of Virginia in Richmond, where he also completed his general surgery training. He completed a residency in urology at the Eastern Virginia Graduate School of Medicine. Dr. Eure is a fellow of the American College of Surgeons. He was recently honored with being chosen into the American Urological Association’s Young Urologist Leadership Program.

As Director of Clinical Research for Devine Tidewater Urology and Urology of Virginia, Dr. Eure is an active researcher in various areas of urologic disease, including the treatment of BPH and the prevention of prostate cancer. He has published his findings in such journals as *Journal of Urology®* and *Urology*, and has presented at a number of national meetings, including American Urological Association annual meetings.

**Harris E. Foster Jr., M.D.**
Professor of Surgery  
Section of Urology  
Yale University School of Medicine  
New Haven, CT

Dr. Harris E. Foster, Jr., M.D. received his undergraduate degree in Biology from the University of Michigan in Ann Arbor. He subsequently attended the University of Miami School of Medicine in Miami, Florida where he graduated with honors. Dr. Foster completed his preliminary general surgery and urology training at the University of Michigan Hospitals. He subsequently joined the faculty at the Yale University School of Medicine where he is currently Professor of Surgery in the Section of Urology. Dr. Foster has been involved in many of the pivotal clinical trials investigating the effects of medical therapy on the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia and their effects on progression of this disease. In addition, he has been involved in attempts to explain some of the results of these investigations utilizing molecular biological techniques. In particular he has been studying the effects of chronic administration of alpha adrenergic antagonists on the alpha receptor system in the rat model. Dr. Foster also has interests in interstitial cystitis and is currently the chair of the National Institutes of Health sponsored Interstitial Cystitis Clinical Research Network.

**Leonard G. Gomella, M.D.**
The Bernard Godwin Jr. Professor of Prostate Cancer Chairman, Department of Urology Thomas Jefferson University  
1025 Walnut Street, Room 1102  
Philadelphia, PA

Dr. Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at Jefferson Medical College and Associate Director of the Kimmel Cancer Center in Philadelphia. Dr. Gomella completed his medical school, general surgery and urology training at the University of Kentucky in Lexington, Kentucky. After a Urologic Oncology Fellowship in the Surgery Branch of the National Cancer Institute in Bethesda, Maryland and he joined the faculty of Jefferson Medical College in 1988 and was appointed Chair in 2002.

Dr. Gomella is involved in both basic science and clinical research in the development of new diagnostic techniques and treatments for prostate, bladder and kidney cancer. Dr. Gomella’s team was first to use RT-PCR to detect micrometastasis metastasis in patients with prostate cancer. He serves as Urology Chair for
Mani Menon, M.D.
Chairman of the Department of Urology at the Henry Ford Health System, the Rajendra and Padma Vattikuti Distinguished Chair in Oncology and Director of the Vattikuti Urology Institute. Dr. Menon is tenured professor of urology at Case Western Reserve University School of Medicine, Cleveland, OH.

Dr. Menon is one of the foremost Urologists in the United States. He graduated from JIMPER Pondicherry and did his residency in Urology at the Brady Urological Institute at John Hopkins, Baltimore, USA with Dr. Patrick Walsh. While working with Dr. Walsh, Dr. Menon developed a technique to measure androgen receptors in the human prostate, the first such measurement. Later, he moved to Washington University in St. Louis where, within two years, he became the youngest tenured clinical faculty member. The techniques involved in nerve-sparing radical prostatectomy were being developed by Walsh when Dr. Menon was at Hopkins. This enabled him to become one of the first surgeons in the world to perform this delicate operation, while he was in St. Louis. In 1983, he moved to the University of Massachusetts Medical School, to start the Division of Urological and Transplantation Surgery there.

At age 34, he became the youngest chairman of Urology in the USA. Under Dr. Menon’s leadership, the Department at the University of Massachusetts became the largest in New England and one of the best in the country as ranked by the U.S. News and World Report. In 1997, Dr. Menon was recruited to Henry Ford Hospital to invigorate the prostate cancer program there.

Dr. Menon’s early interests were in reconstructive surgery for complex renal stones, while his research interests were in cell-crystal interactions as they relate to renal stones. At Henry Ford Hospital, Dr. Menon and his team developed techniques for robotic surgery in general and robotic prostatectomy in particular. The operation was redesigned to take advantage of the features of the robot. Arguably, the robotic approach that Menon has developed --- Vattikuti Institute Prostatectomy or VIP has become the gold standard for the surgical treatment of prostate cancer. The enhanced nerve sparing techniques that the Menon team developed, the “veil of Aphrodite”, promises to dramatically improve erectile function outcomes following radical prostatectomy.

Dr. Menon has published more than 250 papers, primarily in the field of robotic surgery, renal transplantation and urolithiasis. His work has appeared in the major urological journals as well as in the Journal of Clinical Investigation, the Journal of Biological Chemistry, the American Journal of Physiology, Proceedings of the National Academy and the New England Journal of Medicine. He is a recipient of the Gold Cystoscope award of the American Urological Association and a member of the American Association of Genitourinary Surgeons and the Clinical Society of GU Surgeons. He is a past member of the National Kidney and Urological Disease Advisory Board and a Trustee of the American Board of Urology. Dr. Menon is profiled in the Best Doctors of America and the International Who’s Who in Biology and Chemistry.

Katsuyuki Kuratsukuri
Assistant Professor
Department of Urology
Osaka City University School of Medicine
Osaka, Japan

Bio not available at time of publication.

Michael Koch, M.D.
Chairman and Professor
Indiana University School of Medicine
Indianapolis, IN

Dr. Koch completed his general surgery training and a year of research fellowship at Dartmouth Medical School from 1981 though 1984 and then went on to complete his urology training and serve on the faculty at Vanderbilt University School of Medicine until 1998. Dr. Koch then was appointed as the Chairman of the Department of Urology at Indiana University School of Medicine. He has an active interest in general oncology with focused areas in prostate and bladder cancer. The Department at Indiana is internationally recognized for its contributions to the treatment of most GU malignancies but particularly testis cancer. Dr. Koch is a member of the GU Surgeons and is currently a trustee of the American Board of Urology.

Mani Menon, M.D.
Henry Ford Health System
The Raj and Padma Vattikuti Distinguished Chair
Director, Vattikuti Urology Institute
Detroit, MI

Mani Menon, M.D., is chairman of the Department of Urology at the Henry Ford Health System, the Rajendra and Padma Vattikuti Distinguished Chair in Oncology and Director of the
Tatsuya Nakatani  
Professor  
Department of Urology  
Osaka City University School of Medicine  
Osaka, Japan

Nobuyasu Nishisaka, M.D.  
Assistant Professor  
Osaka City University School of Medicine  
Osaka, Japan

Allan B. Patrick, M.D.  
Head of Urology  
River Valley Health  
Fredericton, New Brunswick  
Canada

James Regan, M.D.  
James B. Regan, M.D. is currently Chair of the American Urological Association’s Health Policy Council and the AUA representative to the AMA’sRelative Value Update Committee (RUC). He is a member of the AUA Coding and Reimbursement Committee, Patient Safety and Quality Improvement Committee and the Pay for Performance Task Force (P4P) and serves on the Health Policy Committee of the Mid Atlantic Section of the AUA. He has previously served as vice chair of the Health Policy Council and as the AUA’s representative to the AMA’s Practice Expense Advisory Committee (PEAC). He is a former President of the Washington Urologic Society and is currently an Associate Professor of Urology at Georgetown University Medical Center in Washington, D.C.

Grannum R. Sant, M.D.  
VP and Head of Urology Portfolio  
US Medical Affairs, sanofi-aventis  
Professor of Urology, Tufts University School of Medicine

Peter C. Scardino, M.D.  
Chair, Department of Urology  
Head, Prostate Cancer Program  
Memorial Sloan-Kettering Cancer Center  
New York, NY

Dr. Patrick was born in Chapleau Ontario but spent most of his life in the Maritimes. Growing up in Fredericton, NB, he attended UNB where he received his BA in Biology and Psychology in 1978. He then attended Dalhousie University where he graduated in Medicine in 1984. He took his Urology training also at Dalhousie, finishing in 1989. A clinical fellowship in Lithotripsy preceded his move to Fredericton where he has practiced since. He has held many positions at local regional and national levels. He has been Head of Urology for the Dr. Everett Chalmers Hospital and for the Region, River Valley Health, since 1991. He was instrumental in the development of New Brunswick’s Mobile Lithotripsy Program, which has run successfully since 1993. He has served on the Board of Directors of the New Brunswick Medical Society and been member and Chair of many NBMS Committees most recently as Chair of the NBMS Information Technology Committee. He has served on the Board of the Canadian Urological Association, and been a member of and Chair of the CUA Socioeconomics Committee. He is currently a Board representative of the Northeastern Section of the American Urological Association. He has served on many industry advisory boards and has a busy speaking schedule. He runs a general Urology practice, with emphasis on Female Incontinence and Clinical Trials. Dr. Patrick resides in Fredericton, NB with his wife, Shelley, and children Rebecca, Ian and Katherine.

James Regan, M.D.  
James B. Regan, M.D. is currently Chair of the American Urological Association’s Health Policy Council and the AUA representative to the AMA’s Relative Value Update Committee (RUC). He is a member of the AUA Coding and Reimbursement Committee, Patient Safety and Quality Improvement Committee and the Pay for Performance Task Force (P4P) and serves on the Health Policy Committee of the Mid Atlantic Section of the AUA. He has previously served as vice chair of the Health Policy Council and as the AUA’s representative to the AMA’s Practice Expense Advisory Committee (PEAC). He is a former President of the Washington Urologic Society and is currently an Associate Professor of Urology at Georgetown University Medical Center in Washington, D.C.

Grannum R. Sant, M.D.  
VP and Head of Urology Portfolio  
US Medical Affairs, sanofi-aventis  
Professor of Urology, Tufts University School of Medicine

Peter C. Scardino, M.D.  
Chair, Department of Urology  
Head, Prostate Cancer Program  
Memorial Sloan-Kettering Cancer Center  
New York, NY

Dr. Scardino is recognized internationally as an expert in the early detection and surgical treatment of prostate cancer. He has pioneered techniques to decrease the effects of surgery on urinary and sexual function and to increase the chances of long term control of cancer by total removal of the prostate. Dr. Scardino and his colleagues are using modern medical informatics (artificial intelligence) to develop methods to predict the aggressiveness of prostate cancers and to determine whether some cancers may not need to be treated. His research has also focused on the identification of tissue and genetic markers that signal the behavior of a prostate cancer. He has special experience in the treatment of prostate cancers that recur after surgery or radiation therapy and is currently studying the benefits of focal, image-guided therapy for very early cancers.
Nakhil Shah, M.D.
Director, Minimally Invasive & Robotic Urology
Saint Joseph’s Hospital of Atlanta
Urology Specialists of Atlanta, LLC
Atlanta, GA

Dr. Nikhil L. Shah currently serves as the Director of Minimally Invasive and Robotic Urology at Saint Joseph’s Hospital of Atlanta. He trained at the Vattikuti Urology Institute under Dr. Mani Menon. During his training, Dr. Shah completed a NIH-NIDDK Urologist-Scientist Research Fellowship with Dr. Martin Sanda at the University of Michigan. In addition, he earned a degree in Health Management and Policy at the University of Michigan’s School of Public Health. He has played an active role in leadership and policy related issues with the American Medical Association (AMA) and the American Urologic Association (AUA). As a resident in Urology, Dr. Shah helped to create the AUA Residents Committee and served as its Chair for 3 years. He recently received a Distinguished Service Award from AUA President, Dr. Lawrence S. Ross, M.D., for his service, dedication and leadership. Dr. Shah continues to remain active and currently serves on the AUA’s Coding and Reimbursement Committee. In addition, he maintains an active role in local, national and international medical relief organizations for underserved people.

Taizo Shiraishi, M.D.
Professor
Department of Pathology
Mie University School of Medicine
Tsu, Japan

Bio not available at time of publication.

Robert G. Uzzo, M.D.
Associate Professor of Surgery
Director of Urologic Oncology Research
Department of Urologic Oncology
Fox Chase Cancer Center
Temple University School of Medicine
Philadelphia, PA

Dr. Uzzo graduated summa cum laude and valedictorian from Union College prior to attending Cornell University Medical College. He completed 2 years of general surgical training at The New York Hospital - Cornell Medical Center and Memorial Sloan Kettering Cancer Center under the tutelage of G. Thomas Shires, M.D. Dr. Uzzo went on to complete 4 years of urologic surgical training also at The New York Hospital - Cornell Medical Center and Memorial Sloan Kettering Cancer Center under the guidance of E. Darracott Vaughan M.D. He then went on to become an American Foundation for Urological Diseases Scholar in Urological Oncology at the Cleveland Clinic. In addition, he completed a second fellowship in Renal Vascular Surgery and Transplantation under the direction of Andrew C. Novick, M.D.

Dr. Uzzo is currently an Associate Professor of Surgery at Fox Chase Cancer Center and Temple University School of Medicine. He has an active and funded lab researching the basic mechanisms of kidney and prostate cancer. His clinical interests are in minimally invasive urological oncology. He is the national urology principle investigator for E.C.O.G. 2805 (A.S.S.U.R.E.) – a cooperative group trial studying the role of adjuvant tyrosine kinase inhibitors in intermediate and high-risk kidney cancer. He has authored more than 100 peer reviewed articles and chapters in urology and urologic oncology and has been the recipient of numerous awards from the American Association of Cancer Research, the Society for Basic Urological Research and the Society of Urological Oncology.
Publication of Abstracts – 2006

The Board of Directors of the NS-AUA is pleased to announce that all accepted abstracts (podium and poster presentations) of the 2006 Annual Meeting have been published in the August issue of The Canadian Journal of Urology with generous support from GYRUS ACMI. A copy of this issue of the journal will be distributed when you arrive at the registration desk.

On behalf of the authors, the Executive Officers extend its sincerest thanks and appreciation to The Canadian Journal of Urology and GYRUS ACMI for their generosity. The Canadian Journal of Urology is the officially endorsed journal of the Canadian Urological Association and is indexed in Medline and Index Medicus. The journal welcomes your articles or manuscripts for review and consideration for profitable publication. For additional information on submitting manuscripts or subscription information, contact: Editor-in-Chief, Lawrence H. Koltz, M.D., F.R.C.S.C.

The Canadian Journal of Urology (CJU)
c/o Lena Georgieff
2330 Ward Street, Suite 604
St. Laurent, Quebec H4M 2V6 Canada
Phone: 514-744-1184
Fax: 514-744-1138
E-mail: l.georgieff@canjurol.com
Web: www.canjurol.com

*A copy of the August edition of CJU is included in your bag for referencing this year’s abstracts.

Registration Hours
4th Floor Foyer
Wednesday: 5:00 – 7:00 p.m.
Thursday: 7:00 a.m. – 4:00 p.m.
Friday: 7:00 a.m. – 4:00 p.m.
Saturday: 7:00 a.m. – 10:00 a.m.

Spouse Lounge Hours
New Brunswick Room
Thursday: 2:00 – 5:00 p.m.
Friday: 8:00 a.m. – 4:00 p.m.
Saturday: 8:00 a.m. – 1:00 p.m.

Exhibit Hall Hours
Confederation 2, 3
Thursday: 11:30 a.m. – 1:00 p.m.
5:30 – 7:00 p.m.
Friday: 10:00 a.m. – 3:00 p.m.
Saturday: 9:00 a.m. – 12:00 p.m.

Speaker Ready Room
Nova Scotia Room
Thursday: 12:30 – 7:00 p.m.
Friday: 6:30 a.m. – 7:00 p.m.
Saturday: 6:30 – 11:00 a.m.
**Thursday, September 7, 2006**

8:30 – 9:30 a.m.  
Live Surgery 1st Case  
Percutaneous Nephrolithotripsy –  
John D. Denstedt, M.D.  
Moderator: Hassan Razvi, M.D.  
At the conclusion of this session, participants will be able to:  
• Explain alternative surgical approaches and treatments for management of patients with kidney stones.

9:30 – 10:30 a.m.  
Intuitive Robotic Video Session  
Randy Fagin, M.D.  
At the conclusion of this session, participants will be able to:  
• Describe the latest advances and techniques in robotics surgery for urology patients.

10:30 – 11:30 a.m.  
Live Surgery 2nd Case  
Ureteroscopy with Laser –  
John D. Denstedt, M.D.  
Moderator: Hassan Razvi, M.D.  
At the conclusion of this session, participants will be able to:  
• Explain alternative surgical approaches and treatments for management of patients with kidney stones.

11:30 a.m.–1:00 p.m.  
Sneak Peek Luncheon in Exhibit Hall

1:00 – 3:00 p.m.  
State-of-the-art Lectures 1-4  
Moderators: Kevin Pranikoff, M.D.  
James Wilson, M.D.  
At the conclusion of this session, participants will be able to:  
• Explain alternative pharmacologic treatments and management of patients with Prostate Cancer, Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia, and Renal Cell Cancer.

1:00 p.m.  
State-of-the-Art Lecture I  
Management of Prostate Cancer – Peter T. Scardino, M.D.

1:30 p.m.  
State-of-the-Art Lecture II  
Recent advances in the Pharmacologic Treatment of BPH Harris E. Foster Jr., M.D.,  
Supported by a grant from sanofi-aventis Urology

2:00 p.m.  
State-of-the-Art Lecture III  
The Role of PDE-5 Inhibitors in Erectile Dysfunction Gerald B. Brock, M.D.  
Supported by a grant from Pfizer Inc.

3:00 – 3:30 p.m.  
Break

3:30 – 5:00 p.m.  
State-of-the-art Lectures 5-7

3:30 p.m.  
State-of-the-Art Lecture VI  
New Treatment Paradigms for Renal Cell Carcinoma Robert Uzzo, M.D.  
Supported by a grant from Bayer Pharmaceuticals

4:00 p.m.  
State-of-the-Art Lecture VII  
An Update on Minimally Invasive Treatments and the Evolution of Lasers – Gregg R. Eure, M.D.  
Supported by a grant from Boehringer-Ingelheim

REGISTER ON LINE AT WWW.AUANET.ORG/NORTHEASTERN/
4:30 pm  State-of-the-Art Lecture VII
ABO-Incompatible Kidney Transplantation in Japan
Tatsuya Nakatani, M.D.
"Management of BPH"
Nobuyasu Nishisaka, M.D.

5:00 pm  Current Status of Management of Prostate Cancer in Japan
Katsuyuki Kuratsukuri, M.D.
"Latent prostatic cancer in the USA and Japan: An international comparison and chronological change"
Taizo Shiraishi, M.D.
Four presentations by Japanese guests supported by a grant from Astellas Pharma, Inc.

5:30 – 7:00 p.m.  Exhibit Hall Grand Opening
Welcome Reception

7:00 p.m.  Optional Dine Arounds

Friday, September 8, 2006

6:45 – 7:45 a.m.  Residents' Breakfast Session

7:00 – 8:00 a.m.  Industry Sponsored Breakfast Symposium
Issues and Controversies in the Management of Prostate Cancer with Hormonal Therapy
Supported by a Grant from Watson Pharmaceuticals

8:00 a.m.  Welcome and Introduction
Gabriel P. Haas, M.D.
Northeastern Section of the AUA, President
Paul F. Schellhammer, M.D.
American Urological Association, President-Elect

8:10 – 9:00 a.m.  Podium Session I—Prostate Cancer
Moderators: Joel B. Nelson, M.D.
Pierre I. Karakiewicz, M.D.
Supported by a Grant from GlaxoSmithKline
At the conclusion of this session, participants will be able to:
• Describe areas of clinical research in prostate cancer, and identify areas of controversy in the treatment of prostate cancer patients.
• Identify recent developments in the clinical and pathological staging of prostate cancer.
• Describe pharmacological and surgical options for treating patients with different stages of prostate cancer.

8:10 a.m.  1. Extended Biopsies on Autopsy Prostates: Staging of Microfocal Cancers
Nicolas B. Delongchamps, M.D., Vishal Chandan, M.D., Richard Jones, Ph.D., Gregory Threatte, M.D., Mary Jumbelic, M.D., Gustavo de la Roza, M.D., Gabriel P. Haas, M.D.
Upstate Medical University, Syracuse, NY, USA.

8:17 a.m.  2. The Predictive Accuracy of the Partin Tables in Men with PSA Values in Excess of 20 Ng/ml May Be Limited
Vincent Fradet, M.D., Felix K.-H. Chun,
Alberto Briganti, Paul Perotte, Francesco Montorsi, Markus Graefen, Patrizio Rigatti, Hartwig Huland, Pierre I. Karakiewicz
University of Montreal Health Center, Montreal, PQ, Canada.

8:24 a.m.  3. Treatment of Localized Prostate Cancer with High Intensity Focused Ultrasound (HIFU): Preliminary results of the North American Experience
Magdy M. Hassouna, M.D. Ph.D. FRCSC
FACS, William Orovian, M.D. FRCSC,
Edward Woods, M.D. FRCSC, Mohamed Elkellini, M.D., John Warner, M.D. FRCSC.
Don Mills Surgical Center, Toronto, ON, Canada.

8:31 a.m.  4. Extended Lymphadenectomy Should be Performed in Patients with PSA > 6, Biopsy Gleason Score 7-10 and Stage t2 or Higher Prostate Cancer
Khaled Shahrour, M.D., Alberto Briganti,
Felix K.-H. Chun, Francesco Montorsi,
Patrizio Rigatti, Pierre I. Karakiewicz
University of Montreal Health Center, Montreal, PQ, Canada.

8:38 a.m.  5. Bicalutamide Monotherapy for Biochemical Recurrence of Prostate Cancer with Supplemental Androgen Blockade
Seth A. Capello, M.D., Ronald P. Kaufman, Jr., M.D.
Albany Medical College, Albany, NY, USA.

8:45 a.m.  6. Prostate biopsy by CT-Guided Percutaneous Paracoccygeal Technique
David B. Lillie, M.D.
SUNY at Buffalo, Kenmore, NY, USA.

8:52 a.m.  7. What is the Ideal Extent of Pelvic Lymphadenectomy (PLND)? A Sensitivity Analysis
Khaled Shahrour, M.D., Alberto Briganti,
Felix K.-H. Chun, Francesco Montorsi,
Patrizio Rigatti, Pierre I. Karakiewicz
University of Montreal Health Center, Montreal, PQ, Canada.

9:00 a.m.  Adjourn

9:00 – 11:45 a.m.  Tour Options for Spouses

9:00 – 9:30 a.m.  Guest Lecture: Lymph Node Dissection in GU Surgery
Michael Koch, M.D.
Supported by a Grant from GlaxoSmithKline
9:30 – 10:00 a.m.  Point Counterpoint
Open vs. Robotic vs. Laparoscopic Prostatectomy
Moderator: TBD
Panelists: Peter R. Carroll, M.D.
Jean V. Joseph, M.D.
Ali Moinzadeh, M.D.
Supported by a Grant from GlaxoSmithKline

9:30 – 10:30 a.m.  Moderated Poster Session I—Prostate Cancer
Moderators: Ali Moinzadeh, M.D.
J. Paul Whelan, M.D.

At the conclusion of this session, participants will be able to:
• Describe areas of clinical research in prostate cancer.
• Identify factors that can predict lymph node invasion or positive margins.
• Identify areas of controversy in the treatment of prostate cancer patients.
• Describe pharmacological and surgical options for treating patients with different stages of prostate cancer.

9:30 a.m.  Welcome and Introductions

9:35 a.m.  P1. Validation of a Nomogram for Prediction of Side-specific Extracapsular Extension at Radical Prostatectomy
University of Montreal Health Center, Montreal, PQ, Canada.

9:38 a.m.  P2. Number of Lymph Nodes Removed and Examined and the Continent of Origin Represent the Foremost Predictors of Lymph Node Invasion in Men with Clinically Localized Prostate Cancer
University of Montreal Health Center, Montreal, PQ, Canada.

9:41 a.m.  P3. Clinical Complications of Extended Lymphadenectomy (PLND) in Patients Affected by Localized Prostate Cancer Undergoing Radical Retropubic Prostatectomy at a Single Institution
University of Montreal Health Center, Montreal, PQ, Canada.

9:44 a.m.  P4. Validation of a Nomogram Predicting the Probability of Lymph Node Invasion (LNI) Based on the Extent of Pelvic Lymphadenectomy (PLND)
University of Montreal Health Center, Montreal, PQ, Canada.

9:47 a.m.  P5. Effect of Surgical Margins on Cancer Control Outcomes After Radical Prostatectomy: When Do Margins Matter?

9:50 a.m.  P6. Effect of Autologous Blood Transfusion on Predictive Accuracy of Biochemical Recurrence after Radical Prostatectomy
University of Montreal Health Center, Montreal, PQ, Canada.

9:53 a.m.  P7. Surgical Margin Status in European Versus North American Patients at Radical Prostatectomy
University of Montreal Health Center, Montreal, PQ, Canada.

9:56 a.m.  P8. PSA Represents a Highly Accurate Predictor of Pathologic Stage and Surgical Outcomes
University of Montreal Health Center, Montreal, PQ, Canada.

Erin P. Gibbons, M.D., Ryan P. Smith, M.D., Sushil B. Beriwal, M.D., Krishna Komanduri, Ph.D., Ronald M. Benoit, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
10:02 a.m.  **P10.** Significant Upgrading Affects One in Four Men Diagnosed with Prostate Cancer Predictive Nomogram


University of Montreal Health Center, Montreal, PQ, Canada.

10:05 a.m.  **P11.** Improved Survival with Sipuleucel-T (APC8015) in Men with Advanced Prostate Cancer

Laurence Klotz, M.D.¹, Mark Frohlich, M.D.²

¹Sunnybrook & Women's College HSC, Toronto, ON, Canada, ²Dendreon Corporation, Seattle, WA, USA.

10:08 a.m.  **P12.** The Effect of Surgical Volume on Failure Free Survival After Radical Prostatectomy in the Province of Quebec

Claudio Jeldres, M.D., Serge Benayoun, Alvaro Ramirez, Paul Perrotte, Michael McCormack, Francois Benard, Luc Valiquette, Fred Saad, Pierre I. Karakiewicz.

University of Montreal Health Center, Montreal, PQ, Canada.

10:11 a.m.  **P13.** Poor Overall Survival in Men Treated with definitive Radiotherapy Without Evidence of Disease Relapse—Are We Treating too Many Men with Radiotherapy?

Claudio Jeldres, M.D., Paul Perrotte, Michael McCormack, Fred Saad, Pierre I. Karakiewicz.

University of Montreal Health Center, Montreal, PQ, Canada.

10:14 a.m.  **P14.** External Beam Radiotherapy Outcomes in Septa- and Octogenarians.

Claudio Jeldres, M.D., Paul Perrotte, Jean-Paul Bahary, Fred Saad, Pierre I. Karakiewicz.

University of Montreal Health Center, Montreal, PQ, Canada.

10:17 a.m.  **P15.** A Critical Appraisal of the Ability of Body Mass Index (BMI) to Predict High Grade Prostate Cancer (Pca)


University of Montreal Health Center, Montreal, PQ, Canada.

10:20 a.m.  **P16.** Natural Progression of Men Treated with Hormonal Therapy After Radical Prostatectomy and PSA Recurrence


University of Montreal Health Center, Montreal, PQ, Canada.

10:23 a.m.  **P17.** Impact of Ratio Between Gland Size and Number of Biopsy Cores on Repeat Prostate Biopsy: Development and Internal Validation of A New Repeat Biopsy Nomogram in Men Assessed with 10 or More Cores


University of Montreal Health Center, Montreal, PQ, Canada.

10:00 – 10:30 a.m.

Break

10:30 – 11:30 a.m.

**Moderated Poster Session II—Laparoscopy, Infertility and Stones**

**Moderators:** Jean V. Joseph, M.D.  Anil Kapoor, M.D.

At the conclusion of this session, participants will be able to:

- Describe innovative surgical procedures and their effect on the management of patients with urinary tract disorders, including kidney cancer, prostate cancer, ureteral injury and stones.
- Discuss effect on smoking on sperm quality.

10:30 a.m.  Welcome and Introductions

10:35 a.m.  **P18.** Robot-assisted Extraperitoneal Radical Prostatectomy in Patients with Prior Hernia Surgery

Judd Boczko, M.D., Seth Capello, M.D., Dragan Golijanin, M.D., Ralph Madeb, M.D., Erdal Erturk, M.D., Hiten Patel, M.D., Jean V. Joseph, M.D.

Strong Memorial Hospital, University of Rochester, Rochester, NY, USA.

10:41 a.m.  **P20.** Semen Parameters and DNA Fragmentation in a Smoking Mouse Model

Eric A. Singer, M.D., MA, Sue Schoen, Changyong Feng, Ph.D., Gyun Jee Song, Ph.D., Matthew A. DiMaggio, BS, Jeanne...
P21. The Diagnosis of Late Onset Hypogonadism (Loh) Remains a Clinical and Biochemical Dilemma
Laurel E. Emerson, R.N., Research Coordinator, Angela M. Black, R.N., Research Coordinator, Michael Spevack, Michael Spevack, Irwin Kuzmarov,
H. O’Brien, M.D., University of Rochester Medical Center, Rochester, NY, USA.

P22. Short-term Dutasteride Use Decreases Serum PSA But Has Minimal Effect on Prostate Volume in Men with Prostate Cancer Prior to Robotic Prostatectomy
William Badger, M.D., Michael Perrotti, Michael Moran, James Belarmino, Daryl McLeod
Albany Medical Center, Albany, NY, USA, Saint Peter’s Hospital, Albany, NY, USA.

P23. The Influence of Laparoscopy on Partial Nephrectomy Rate for Small Renal Masses
William Badger, M.D., Michael Perrotti, Michael Moran, Daryl McLeod
Albany Medical Center, Albany, NY, USA, Saint Peter’s Hospital, Albany, NY, USA.

P24. Impact of Robotics and Laparoscopy on Surgical Skills: A Comparative Study
Sasha Pavlov-Shapiro, M.D., Boris Kuvshinoff, William E. Brady, MS, Aftaab Nida, BS, Hyung Kim, M.D., James Mohler, M.D., Khurshid A. Guru, MBBS
University at Buffalo, Buffalo, NY, USA, Roswell Park Cancer Institute, Buffalo, NY, USA.

P25. Open Repair for Benign Ureteral Strictures in the Modern Era of Endoscopic Management
Anthony T. Corcoran, M.D., Mark C. Smaldone, Daniel J. Ricchiuti, Timothy D. Averch
University of Pittsburgh, Pittsburgh, PA, USA.

P26. Stone-to-skin Distance Greater than F2-to-skin Distance has no Effect on Shock-wave Lithotripsy Success
Marc C. Smaldone, M.D., Bruce L. Jacobs, M.D., Arlene M. Smaldone, DNSc, CPNP, CDE2, Daniel J. Ricchiuti, M.D., Timothy D. Averch, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA, Columbia University School of Nursing, New York, NY, USA.

P27. Predictors of Shock-wave Lithotripsy Success for Proximal Ureteral Calculi on Non-contrast CT
Eric A. Singer, M.D., MA, Jared D. Christensen, M.D., Judd Boczkko, M.D., Susan Messing, MS, Jean V. Joseph, M.D., Erdal Erturk, M.D.
University of Rochester Medical Center, Rochester, NY, USA.

P28. Effect of Gatorade on Urinary Stone Risk Factors
Danielle D. Sweeney, M.D., Daniel J. Ricchiuti, M.D., Timothy D. Averch, M.D.
University of Pittsburgh, Pittsburgh, PA, USA.

Podium Session II—Bladder Cancer
Moderators: Edward M. Messing, M.D., J. Paul Whelan, M.D.
At the conclusion of this session, participants will be able to:
• Describe areas of clinical research in bladder cancer.
• Identify factors that can affect outcomes in patients with bladder cancer.
• Describe current innovative pharmacological and surgical treatments for patients with bladder cancer.

8. Competing Risks Nomogram Predicting the Probability of Bladder Cancer Recurrence After Cystectomy Can Reliably Distinguish Between Those Destined to Recur and Those Who May Die of Other Causes Before Recurrence
University of Montreal Health Center, Montreal, PQ, Canada.

9. Internal Validation of a Competing-Risks Survival Nomogram for Patients Treated with Cystectomy for Bladder Cancer
University of Montreal Health Center, Montreal, PQ, Canada.
10:49 a.m.  10. Impact of Concomitant Carcinoma in Situ on Clinical Outcomes After Radical Cystectomy
University of Montreal Health Center, Montreal, PQ, Canada.

10:56 a.m.  11. Delay in Radical Cystectomy Over 12 Weeks is Not Associated with Adverse Outcome: Results from the Bladder Cancer Research Consortium
University of Montreal Health Center, Montreal, PQ, Canada.

11:03 a.m.  12. Prognostic Significance of Deep Muscular Invasion and Extravesical Extension in Pathological Staging of Bladder Cancer After Radical Cystectomy
University of Montreal Health Center, Montreal, PQ, Canada.

11:10 a.m.  13. Predictive Accuracy, Sensitivity and Specificity of Nuclear Matrix Protein 22 and Urine Cytology for Prediction of Recurrence of Non-transitional Cell Carcinoma of the Bladder
University of Montreal Health Center, Montreal, PQ, Canada.

11:17 a.m.  14. Robot-assisted radical Cystectomy and Pelvic Lymph Node dissection; Initial Experience at Roswell Park Cancer Institute
Khurshid A. Guru, M.D.,’ Hyung L. Kim, M.D.,’ Pamela Piacente, PA, Teresa Danforth, Greg Zimmerman, M.D.,’ James L. Mohler, M.D.,’
Roswell Park Cancer Institute, Buffalo, NY, USA, ‘University of Buffalo, Buffalo, NY, USA.

11:24 a.m.  Discussion

11:30 a.m.  Adjourn

11:30 a.m.–12:00 p.m. Guest Lecture: Superficial Bladder Cancer
Leonard G. Gomella, M.D.

12:00 – 1:00 p.m. Exhibit Hall Open, Lunch Served

1:00 – 2:00 p.m. Podium Session III – Pediatrics
Moderators: Jyoti Upadhyay, M.D.
Ann-Marie Houle, M.D.
At the conclusion of this session, participants will be able to:
• Describe current areas of research in pediatric urology, and identify areas of controversy in treating pediatric patients with anticholinergic therapy.
• Describe novel techniques in the management of children with hydronephrosis, ectopic ureteroceles and ureteropelvic junction obstruction.
• Identify state-of-the-art diagnostic tools in the diagnosis and management of patients with enuresis, renal trauma and nonpalpable testes.

1:00 p.m.  15. Refractory Nocturnal Enuresis: True Benefits of Urology Referral
Suzanne Moyer, RN, William C. Hulbert, M.D., Cheryl Kline, CPNP, Ronald Rabinowitz, M.D., Robert A. Mevorach, M.D.
University of Rochester, Rochester, NY, USA.

1:04 p.m.  16. Radical Bulbar Dissection and TIP Urethroplasty to Correct Proximal Hypospadias with Severe Chordee: Applicability and Outcomes
Marc C. Smaldone, M.D., Glenn M. Cannon, Jr., M.D., Ethan Polsky, M.D., Steven G. Docimo, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

1:11 p.m.  17. Ectopic Ureteroceles in Duplex Systems: Long Term Follow Up After a Staged Approach
Ming-Hsien Wang, M.D., Saul P. Greenfield, M.D., Pierre Williot, M.D., John M. Rutkowski.
Children’s Hospital of Buffalo, Buffalo, NY, USA.

1:18 p.m.  18. Can CT Scan Findings Shorten the Recovery for Grade IV Blunt Renal Trauma in Children?
Glenn M. Cannon, Jr., M.D., Marc C. Smaldone, M.D., Ethan G. Polsky, M.D., Francis X. Schneck, M.D., Mark F. Bellinger, M.D., Steven G. Docimo, M.D., Hsi-Yang Wu, M.D.
Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA.

1:25 p.m.  19. Method to Diagnose Testicular Torsion Using Near Infrared Fluorescence (NIRF) of Intravenous Indocyanine Green (ICG)
Dragan Golijanin, M.D., Ralph Madeb, M.D., Ronald Wood, Ph.D., Jay E. Reeder, Ph.D., Robert Mevorach, M.D., William Hulbert, M.D., Ronald Rabinowitz, M.D., Edward M. Messing, M.D., Jean Joseph.
Departments of Urology and Pathology URMC, SMH, Rochester, NY, USA.
1:39 p.m. 20. Early Experience with Laparoscopic Pyeloplasty for Ureteropelvic Junction Obstruction in Children: Evolution of Technique
Danielle D. Sweeney, M.D., Christine Kim, M.D., Francis X. Schneck, M.D., Steven G. Docimo, M.D.
University of Pittsburgh, Pittsburgh, PA, USA.

1:46 p.m. 21. Another Benefit of Laparoscopy for Non-palpable Testes: Finding Contralateral Hernias
Bulent Onal, M.D., Barry A. Kogan, M.D., F.A.C.S., F.A.A.P.
Albany Medical College, Albany, NY, USA.

1:53 p.m. 22. Anticholinergic Effects on Short-term Memory Recall
Barry A. Kogan, M.D.,1 Karla M. Giramonti, MS FNP1, Leslie F. Halpern, Ph.D2
1The Urological Institute of Northeastern New York, Albany, NY, USA, 2University at Albany, SUNY Department, Albany, NY, USA

2:00 p.m. Adjourn

2:00 – 4:00 p.m. Moderated Poster Session III—Pediatrics, Female Urology, Basic and General Urology
Moderators: Robert Lai, M.D.
Ross G. MacMahon, M.D.
At the conclusion of this session, participants will be able to:
• Describe current areas of research in pediatric urology, and state-of-the-art therapeutic options for managing patients with common and complex pediatric urological problems.
• Describe treatment options for urinary incontinence with emphasis on surgical procedures and therapeutic outcomes.
• Describe current research in prostate cancer.
• Identify safety and tolerability of different pharmacological therapies in a urological disorders

2:00 – 2:30 p.m. Guest Lecture: Pediatric Urology
Curtis A. Sheldon, M.D.

2:30 – 3:00 p.m. Break — Visit Exhibit Hall

3:00 – 3:30 p.m. Stump the Professors
Difficult Cases from the Community
Michael O. Koch, M.D., Peter R. Carroll, M.D., Dean G. Assimos, M.D., Leonard Gomella, M.D.

3:00 p.m. Welcome and Introductions

3:05 p.m. P29. Intravaginal Testicular Torsion: Avoiding Neglect of the Infant and Child
Robert Mevorach, M.D., William Hulbert, Ronald Rabinowitz.
University of Rochester, Rochester, NY, USA.

3:08 p.m. P30. Early Versus Late Treatment of Voiding Dysfunction with Pelvic Neuromodulation
Mohamed Eikelini, M.D., Magdy Hassouna, M.D., Ph.D., FRCS, FACS.
University of Toronto, Toronto, ON, Canada.

3:11 p.m.

3:14 p.m.

3:17 p.m.

3:20 p.m.

3:23 p.m.

3:26 p.m.

P31. Peripheral Benzodiazepine Receptor has Antiapoptotic Effects in Prostate Cancer and is Elevated in Primary and Metastatic Prostate Malignancies
Ardavan Akhavan, BA, Uzma S. Shah, Ph.D., Anil Parvani, M.D., Joel B. Nelson, M.D., Beth R. Pflug, Ph.D.
University of Pittsburgh, Pittsburgh, PA, USA.

P32. Safety and Efficacy of Bladder Botulinum Toxin Injection in the Elderly
Marc C. Smalbone, M.D.,1 Margie O’Leary, M.S.N, R.N,1 Catherine A. Thomas, Ph.D.1
Janet Erickson, B.S.1, Sara Marx, B.S.2, Christopher P. Smith, M.D.2, Michael B. Chancellor, M.D.1
1University of Pittsburgh Medical Center, Pittsburgh, PA, USA, 2Baylor College of Medicine, Houston, TX, USA.

P33. Ureteroscopic Treatment of Stone Disease is Equally Effective in Both Younger and Older Pediatric Populations
Marc C. Smalbone, M.D., Glenn M. Cannon, Jr., M.D., Jeffrey Bassett, Hsi-Yang Wu, M.D., Mark F. Bellingar, M.D., Steven G. Docimo, M.D., Francis X. Schneck, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

P34. Bone Marrow Derived Cells (BM.D.Cs) are Capable of Regenerating Prostate Epithelium: Implications for an Extra-prostatic Source of Prostate Progenitor Cells
Ganesh S. Palapattu, M.D.,1 Alan Meeker, Ph.D.2, Timothy Harris, BS3, Michael Collector, MS2, Saul Sharkis, Ph.D.2, Angelo DeMarzo, M.D., Ph.D.2, Charles Drake, M.D., Ph.D.2, William G. Nelson, M.D., Ph.D.2
1University of Rochester School of Medicine, Rochester, NY, USA, 2Johns Hopkins University School of Medicine, Baltimore, MD, USA.

P35. Initial Experience with the Male Sling Using Composite Graft for Treatment of Stress Urinary Incontinence in Post-prostatectomy Patients
Bashar Omarbasha, M.D., Oleg Shapiro, M.D.
Upstate Medical University, Syracuse, NY, USA.
3:26 p.m. **P36.** The Cost-effectiveness of Suburethral Male Sling for Stress Urinary Incontinence Versus Artificial Urinary Sphincter 800
Oleg Shapiro, M.D., Bashar Omarbasha, M.D.
Upstate Medical University, Syracuse, NY, USA.

3:29 p.m. **P37.** Sildenafil Citrate (Viagra®) is Efficacious and Well Tolerated in Men with Both Erectile Dysfunction and Lower Urinary Tract Symptoms
Evan R. Goldfischer, M.D.,1 Kevin T. McVary, M.D.,2 Li-Jung Tseng, PhD,2 Gené van den Ende, MBBCh2
1Hudson Valley Urology, P.C., Poughkeepsie, NY, USA,
2Feinberg School of Medicine, Northwestern University, Chicago, IL, USA,
3Pfizer Inc, New York, NY, USA.

3:32 p.m. **P38.** Ureteral Access Sheath Usage in Pediatric Ureteroscopy
Glenn M. Cannon, Jr., M.D., Marc C. Smaldone, M.D., Jeffrey C. Bassett, BS, Hsi-Yang Wu, M.D., Mark F. Beilinger, M.D., Steven G. Docimo, M.D., Francis X. Schneck, M.D.
Children’s Hospital of Pittsburgh, Pittsburgh, PA, USA.

3:35 p.m. **P39.** Short-term Independent Outcomes with the Prolieve Thermodilation System for BPH
William P. Conners, III, M.D., Ronald P. Kaufman, Jr., M.D., Badar M. Mian, M.D., Hugh A. G. Fisher, M.D.
Albany Medical College, Albany, NY, USA.

3:38 p.m. **P40.** Progression of Prostate Carcinogenesis in an ERCC1-deficient Prostatic Tissue Recombinant Model
Derek J. Matoka, M.D., Veronica Yao, Ph.D., Dean J. Bacich, Ph.D.
University of Pittsburgh, Pittsburgh, PA, USA.

3:41 p.m. **P41.** The Importance of Pressure-Flow Study for Predicting Postoperative Voiding Difficulties in Women with Stress Urinary Incontinence: A Preliminary Study that Correlates Low Pdet x Qave Value with Postoperative Residual Urine
Hidenori Kawashima, M.D., Ph.D.
Osaka City University Graduate School of Medicine, Osaka, Japan.

3:44 p.m. **P42.** BMI and its Ability to Improve Prediction of Biochemical Recurrence (BCR) After Radical Prostatectomy (RP): Does a Statistically Significant Marker Always Improve Predictive Accuracy in Multivariate Models?

3:47 p.m. **P43.** The Tolerability of Tolterodine is Not Diminished in Older Patients: An Analysis of 5 Randomized, Double-blind, Placebo-controlled Trials
Evan R. Goldfischer, M.D.,1 Dale B. Glasser, Ph.D.,2 Martin Carlsson, MS,3
1Hudson Valley Urology, P.C., Poughkeepsie, NY, USA,
2Pfizer Inc, New York, NY, USA.

3:50 p.m. **P44.** HATS—Health Advocacy in Training Survey
Mike Leveridge, Darren Beiko, D. Robert Siemens.
Queen’s University, Kingston, ON, Canada.

3:53 p.m. **P45.** Genotyping of SRA Isoforms in the Caucasian Prostate Cancer Patients
Shozo Sugita1, Ching Y. Wang1, Tomoaki Tanaka2, Hidenori Kawashima3, Tatsuya Nakatani2, Gabriel P. Haas1
1SUNY Upstate medical university, Syracuse, NY, USA,
2Osaka City University graduate school of Medicine, Osaka, Japan.

3:30 – 4:00 p.m. Podium Session IV—Prostate Cancer Recurrence/Biopsies
Moderators: Badar Mian, M.D.
At the conclusion of this session, participants will be able to:
• Describe areas of clinical research in prostate cancer, and identify areas of controversy in the treatment of prostate cancer patients.
• Identify recent developments in the clinical and pathological staging of prostate cancer.
• Describe pharmacological and surgical options for treating patients with different stages of prostate cancer.

3:30 p.m. **P23.** Prostate Volume and High Grade Prostate Cancer: Are PCPT Findings Right?
University of Montreal Health Center, Montreal, PQ, Canada.

3:37 p.m. **P24.** Number of Positive Cores Does Not Improve Ability in Predicting Pathological Stage and Biochemical Recurrence (BCR)
University of Montreal Health Center, Montreal, PQ, Canada.
25. Prostate Volume at Initial Biopsy is the Most Important Predictor of Repeat Biopsy Outcome: Validation of a Novel Predictive Tool
University of Montreal Health Center, Montreal, PQ, Canada.

26. Impact of Gland Size on Initial 10 or More (+) Core Prostate Biopsy: Development and Internal Validation of a 10+ Cores Biopsy Nomogram
University of Montreal Health Center, Montreal, PQ, Canada.

27. Retroperitoneoscopic Live Donor Nephrectomy: Initial Experience with a Modified Hand-assist Approach
Andrew Feifer, M.D.1, Abrar Khan, M.D.2, Jean Tchervenkov, M.D.2, Mark K. Plante, M.D.2, John-Paul Capolicchio, M.D.1.
1McGill University, Montreal, PQ, Canada,
2University of Vermont, Burlington, VT, USA.

28. Robot-assisted Radical Prostatectomy in Obese Patients
Judd Boczko, M.D., Seth Capello, M.D., Dragan Golijanin, M.D., Ralph Madeb, M.D., Hiten Patel, M.D., Jean V. Joseph, M.D.
Strong Memorial Hospital, University of Rochester, Rochester, NY, USA.

29. Location of Positive Margin and PSA Progression in Patients Undergoing Extraperitoneal Robot-assisted Radical Prostatectomy
Judd Boczko, M.D., Seth Capello, M.D., Dragan Golijanin, M.D., Jorge Yao, Ralph Madeb, M.D., Erdal Erturk, M.D., Hiten Patel, M.D., Jean V. Joseph, M.D.
Strong Memorial Hospital, University of Rochester, Rochester, NY, USA.

30. Early Potency Outcomes After Cautery-free Versus Bipolar Neurovascular Bundle Preservation During Extraperitoneal Robotic Prostatectomy
Judd Boczko, M.D., Seth Capello, M.D., Mary Mathe, PA, Erdal Erturk, M.D., Hiten Patel, M.D., J V. Joseph, M.D.
Strong Memorial Hospital, University of Rochester, Rochester, NY, USA.

31. Robot-assisted Anterior Exenteration: Technique and Case Series
Mark A. Nogueira, M.D.1, Hyung L. Kim, M.D.1, Pamela Placente, PA2, Gregg E. Zimmerman, M.D.1, James L. Mohler, M.D.3, Khurshid A. Guru, M.D.3.
1State University of New York at Buffalo, Buffalo, NY, USA, 2Roswell Park Cancer Institute, Buffalo, NY, USA.

32. Intermediate Term Follow up of Laparoscopic Renal Tumor Cryoablation: Proceed with Caution
Gregory Spana, M.D., Amar Singh, M.D., Bijan Shekariz, M.D., Alireza Moinzadeh, M.D.
SUNY—Upstate Medical University, Syracuse, NY, USA.
8:47 a.m. 33. Laparoscopic Extravesical Ureteral Reimplantation: Initial Experience with Two Cases
Margaret Roth, M.D., Amar Singh, Ali Moinzadeh, M.D.
SUNY-Upstate Medical University, Syracuse, NY, USA.
9:23 a.m.

8:54 a.m. Discussion

9:00 a.m. Adjourn

9:00 – 10:00 a.m. Moderated Poster Session IV—Other Cancer
Moderators: Ronald P. Kaufman, M.D.
At the conclusion of this session, participants will be able to:
• Describe current areas of research in Urologic cancers.
• Identify areas of controversy in treating patients and state-of-the-art therapeutic options for managing patients with common and complex urological problems.
9:26 a.m.

9:00 a.m. Welcome and Introductions

9:05 a.m. P46. Effect of Perioperative Blood Transfusion on Prostate Cancer Recurrence
Satish Sharma, M.D.\textsuperscript{1}, James Mohler, M.D.\textsuperscript{2}
Beneranda S. Ford, M.D.\textsuperscript{1}
\textsuperscript{1}Roswell Park Cancer Institute, Buffalo, NY, USA,
\textsuperscript{2}SUNY @ Buffalo, Buffalo, NY, USA
9:29 a.m.

9:08 a.m. P47. Single-centre Evaluation of the NMP-22 Point-of-care Assay as an Adjunctive Tool for the Diagnosis of Bladder Cancer
Sylvia M. Robb, RN, Research Coordinator;
Laurel Emerson, RN Research Coordinator;
Chris Kong, Medical Student;
Alvaro Morales, M.D. FRCS.C.
Queens University, Kingston, ON, Canada.
9:32 a.m.

9:11 a.m. P48. Observation of Large Renal Masses: Insight into the Natural History of Kidney Cancers
Ashley R. Cox, M.D., Joseph L. Chin, M.D.,
Stephen E. Pautler, M.D.
University of Western Ontario, London, ON, Canada.
9:35 a.m.

9:14 a.m. P49. Post-prostatectomy Incontinence: Factors Affecting Treatment Success
Paul H. Johnston, M.D., D. Robert Siemens,
M.D., Janice Jackson, R.N.
Queen’s University, Kingston, ON, Canada.
9:38 a.m.

9:20 a.m. P51. Snowboarding and Blunt Renal Trauma: A Review of Clinical Experience
James M. Belarmino, M.D.\textsuperscript{1}, Michael Perrotti, M.D.\textsuperscript{2}
\textsuperscript{1}Albany Medical Center, Albany, NY, USA,
\textsuperscript{2}St. Peters Hospital, Albany, NY, USA.

9:23 a.m. P52. Preoperative and Intraoperative Imaging of Penile Sentinel Lymph Nodes (SLN) Using Indocyanine Green (ICG) Near Infrared Fluorescence (NIRF)
Dragan Golijanin, M.D., Ralph Madeb, M.D.,
Ronald Wood, Ph.D., Jay E. Reeder, Ph.D.,
Vikram Dogra, M.D., Jorge Yao, M.D.,
Jean Joseph, Edward M. Messing, M.D.
Department of Urology, Pathology and Radiology, URMC,SMH, Rochester, NY, USA.

9:26 a.m. P53. Intraoperative Sentinel Lymph Node (SLN) Detection Using Near Infrared Fluorescence (NIRF) After Intravesical Indocyanine Green (ICG) Administration to Up II / SV 40T Mouse Model of Bladder Cancer
Dragan Golijanin, M.D., Aimee Johnson,
MS, Jay E. Reeder, Ph.D., Ronald Wood,
Ph.D., Vikram Dogra, M.D., Jean Joseph,
M.D., Edward M. Messing, M.D.
Departments of Urology, Pathology and Radiology, URMC,SMH, Rochester, NY, USA.

9:29 a.m. P54. The Effect of Competing Mortality on the Risk of Cancer-specific Survival in Kidney Cancer
Quoc-Dien Trinh, M.D., Pierre I. Karakiewicz,
Paul Perrotte, Alberto Briganti,
Felix K.-H. Chun, Jean-Jacques Patard
University of Montreal Health Center, Montreal,
PQ, Canada.

9:32 a.m. P55. Internal Validation of a Competing-Risks Survival Nomogram for Patients Treated with Radical Prostatectomy (RP) for Clinically Prostate Cancer (PCa).
Quoc-Dien Trinh, M.D., Christopher Porter,
Alberto Briganti, Felix K.-H. Chun,
Pierre I. Karakiewicz
University of Montreal Health Center, Montreal,
PQ, Canada.

9:35 a.m. P56. The Effect of Competing Mortality on Prostate Cancer (PCa)-specific Survival and Rate of Metastatic Disease after Radical Prostatectomy (RP)
Christopher Porter, M.D., Alberto Briganti,
Felix K.-H. Chun, Koichi Kodama, Robert Gibbons,
Roy Jnr. Correa, Paul Perrotte,
Pierre I. Karakiewicz
University of Montreal Health Center, Montreal,
PQ, Canada.

9:38 a.m. P57. The Birt-Hogg-Dube Tumor Suppressor
is Predominantly Localized in the Nucleolus and Regulates IFn-γ Induced JAK-STAT1-ISRE Pathway
Dakun Wang, Ph.D., Edward M. Messing, M.D., Guan Wu, M.D., Ph.D.
University of Rochester, Rochester, NY, USA.

9:41 a.m.  P58. Management of Bilateral Synchronous Renal Cell Carcinoma in a Single Procedure
Bruce L. Jacobs, M.D., Erin P. Gibbons, M.D., Ronald L. Hrebinko, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

9:44 a.m.  P59. The Effect of Competing Mortality on The Risk of Bladder Cancer Recurrence and Bladder Cancer-specific Survival
University of Montreal Health Center, Montreal, PQ, Canada.

9:47 a.m.  P60. The Von Hippel-Lindau Tumor Suppressor Interacts with Receptor for Activated C Kinase 1 and Represses Insulin-Like Growth Factor I-induced Renal Carcinoma Cell Invasiveness
Guan Wu, M.D., Ph.D.
Medical Center, UR, Rochester, NY, USA.

9:50 a.m.  P61. Development and External Validation of Nomograms Predicting Necrosis vs. Teratoma vs. Residual Cancer at Post-chemotherapy Resection of Residual Masses
Pierre I. Karakiewicz, M.D., Paul Perrotte, Yvonne Vergrouwe, Evout W. Steyerberg.
University of Montreal Health Center, Montreal, PQ, Canada.

9:53 a.m.  P62. Renal Preservation Following Partial Nephrectomy as Measured by Creatinine Clearance
Aaron T. D. Clark, M.D., Kunal Jana, M.D., Chris Morash, M.D., Ilias Cagiannos, M.D.
University of Ottawa, Ottawa, ON, Canada.

10:00 a.m. Adjourn

9:00 – 9:30 a.m. Slotkin Lecture — Computer Assisted Robotic Surgery (CARS): A Paradigm Shift After 2600 Cases
Mani Menon, M.D.

9:00 a.m.– 12:00 p.m. Exhibit Hall Open

9:30 – 10:00 a.m. Break — Visit Exhibit Hall

10:00 – 10:30 a.m. Podium Session VI — Stones
Moderators: Erdal Erturk, M.D.
Hassan Razvi, M.D.

At the conclusion of this session, participants will be able to:
• Describe areas of clinical research in calculus disease.
• Describe current alternatives in the surgical treatment for patients with kidney and ureteral stones in the adult and pediatric population.
• Identify factors affecting outcomes in different urological cancers.

Welcome and Introductions

10:00 a.m.  34. Cross-Sectional Area: A Novel Predictor of Ureteral Stone Outcome
Kirk Roth, BSCh 2001, James Wilson, M.D., Paul Johnston, M.D.
Queen’s University, Kingston, ON, Canada.

10:05 a.m.  35. The Ureteroscopic Management of Nephrolithiasis: 5-year Experience in a Pediatric Institution
Marc C. Smaldone, M.D., Glenn M. Cannon, Jr., M.D., Jeffrey Bassett, Ethan Polsky, M.D., Hsi-Yang Wu, M.D., Mark F. Bellinger, M.D., Steven G. Docimo, M.D., Francis X. Schneck, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

10:12 a.m.  36. The Staged Retrograde Endoscopic Lithotripsy as an Alternative to PCNL in Select Patients with Large Renal Calculi
Daniel Ricchiuti, M.D.,1 Benjamin Stockton, M.D.,1 Marc Smaldone, M.D., Jeffrey Bassett, Hsi-Yang Wu, M.D., Mark F. Bellinger, M.D., Steven G. Docimo, M.D., Francis X. Schneck, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

10:19 a.m.  37. Staged Retrograde Endoscopic Lithotripsy as an Alternative to PCNL in Select Patients with Large Renal Calculi
Daniel Ricchiuti, M.D.,1 Benjamin Stockton, M.D.,1 Marc Smaldone, M.D., Jeffrey Bassett, Hsi-Yang Wu, M.D., Mark F. Bellinger, M.D., Steven G. Docimo, M.D., Francis X. Schneck, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

10:26 a.m.  38. The Ureteroscopic Management of Lower Pole Stones in a Pediatric Population
Glenn M. Cannon Jr., M.D., Marc C. Smaldone, M.D., Jeffrey Bassett, Ethan Polsky, M.D., Hsi-Yang Wu, M.D., Mark F. Bellinger, M.D., Steven G. Docimo, M.D., Francis X. Schneck, M.D.
University of Pittsburgh Medical Center, Pittsburgh, PA, USA.

10:30 a.m. Adjourn

10:30 – 11:00 a.m. Guest Lecture: Surgical Management of Patients with Complex Nephrolithiasis
Dean G. Assimos, M.D.

11:00 – 11:30 a.m. Guest Lecture
Interstitial Cystitis: Update on Pathology and Treatment
Grannum R. Sant, M.D.

11:30a.m.–12:15p.m. U.S.-Canadian Socioeconomics Update

12:30 – 5:30 p.m. Golf Tournament — Chateau Cartier Resort
1:15 – 4:30 p.m. Tennis — The Ottawa Athletic Club
1:15 – 3:00 p.m. Tours — Options
Nursing Program

Friday, September 8, 2006
7:30 – 8:00 a.m. Breakfast
8:10 – 8:30 a.m. Welcome
Gabriel P. Haas, M.D., Northeastern Section of the AUA, President
Susan Freed, R.N., Urology Nurses of Canada, President
Susan Lipsy, R.N., M.S., C.U.N.P., Society of Urologic Nurses and Associates, Northeast, Regional Director

8:30 – 9:55 a.m. Education Session (1 CEU)
Interstitial Cystitis: Past, Present and Future
Vicki Ratner, M.D., President and Chief Medical Officer, The Interstitial Cystitis Association
Moderator: Amy LoPresti, R.N.

10:00 – 10:15 a.m. Morning Break

10:15 – 11:30 a.m. Education Session (1 CEU)
Vesicoureteral Reflux: Is There a New Perspective?
Jyoti Upadhyay, M.D., F.A.A.P., Chief, Division of Pediatric Urology, SUNY Upstate Medical University, Syracuse, NY.
Moderator: Nancy Bauer, R.N.

11:30 a.m. – 1:30 p.m. Lunch — Exhibit Hall

1:30 – 2:45 p.m. Education Session (1.5 CEU)
GU Pathology (Why are they having a pathologist talk?)
Steve K. Landas, M.D., Departments of Pathology and Urology, SUNY Upstate Medical University, Syracuse, NY.
Moderator: Gina Brothers, R.N., N.P.

2:45 – 3:15 p.m. Afternoon Break

3:15 – 4:15 p.m. Education Session (1 CEU)
Ask Your Colleagues: Management of Adult and Pediatric Enuresis, Obstructive Uropathy and Urinary Tract Infections
Moderator: Amy LoPresti, R.N.

Total: 4.5 CEUs

Saturday, September 9, 2006
7:30 – 8:00 a.m. Breakfast
8:00 – 9:00 a.m. Education Session (1 CEU)
Female Sexual Dysfunction
Bashar Omarbasha, M.D., Medical Director, CNY Male Sexual Diagnostic Center, Oneida, NY
Grannum R. Sant, M.D.

9:00 – 9:30 a.m. Guest Lecture
New Paradigms in Treatment of BPH
Grannum R. Sant, M.D.

9:30 – 10:00 a.m. Break — Visit Exhibit Hall

10:00 – 11:00 a.m. Education Session (1 CEU)
Erectile Dysfunction — Current Evaluation and Management
Jonathan D. Block, M.D., Ph.D., M.B.A., P.F.P.M. Vice-President and Partner, Mohawk Valley Urology, PC Chair, Department of Urology, Faxton-St. Luke’s Healthcare, Utica, NY
Moderator: Susan Lipsy, R.N., M.S., C.U.N.P.

11:00 a.m. – 12:30 p.m. Education Session (1.5 CEU)
Comparison of Current Treatment Strategies for Overactive Bladder, Urge Urinary Incontinence and Female Stress Urinary Incontinence in Canada and the United States
Kevin Victor Power, H.B.A., M.D., F.R.C.S.C., Attending Urologist, Queensway Carleton Hospital, Ottawa, Canada, Robert S. Lai, M.D., Director of Urodynamics, Neurology, and Female Urology Assistant Professor, Department of Urology, SUNY Upstate Medical University, Syracuse, NY.
Moderator: Oleg Shapiro, M.D.

Total: 3.5 CEUs

Exhibit Hall Hours

Thursday, September 7, 2006
11:30 a.m. – 1:00 p.m. Sneak Peek Luncheon
5:30 – 7:00 p.m. Grand Opening Welcome Reception

Friday, September 8, 2006
10:00 a.m. – 3:00 p.m.

Saturday, September 9, 2006
9:00 a.m. – 12:00 p.m.
SOCIAL EVENT INFORMATION:
DINE AROUND

Thursday, September 7, 2006

The following restaurants are currently holding spots for the dine around evening. Please review the list of restaurants and choose the one that you would like to go to for the dine around this evening. Feel free to visit the web sites for each of these restaurants to get a better idea of what the restaurant is like and to review their current menus. A price per person for a three-course dinner—including an appetizer, entree and a dessert and excludes alcohol—has also been provided as a general guide for you. Each restaurant has reserved a limited number of spots for our group. However, if there is a high demand for a particular restaurant, we will try our best to accommodate your request.

On the night of the dine around, staff will meet each group and walk them to the restaurant for their reservations. Reservation times have been booked and are indicated below. Please confirm the reservation time for your restaurant upon registration at the conference. Once you have arrived at the restaurant, the staff will depart and you will be on your own for the rest of the evening.

**Guests will be 100% responsible for paying for their own meal at the restaurants.**

### BUSINESS CASUAL — MID-RANGE RESTAURANTS

**Empire Grill**
20 spots reserved
Reservation Time: 7:00 p.m.
Estimate $35–$65 CDN per person, plus taxes and 15% gratuity
www.empiregrill.com

**Kinki**
30 spots reserved (private room)
Reservation Time: 7:30 p.m.
Asian-fusion food and excellent Sushi selections; including assorted tasting plates. In-vogue Asian inspired dining lounge sporting clean, modern architecture.
Estimate $37–$74 CDN per person, plus taxes and 15% gratuity
www.kinki.ca

**Meditheo Mediterranean Restaurant & Bar**
20 spots reserved
Reservation Time: 7:00 p.m.
Estimate $32–$73 CDN per person, plus taxes and 15% gratuity
www.meditheo.com

**Mezzanotte Italian Bistro**
20 spots reserved
Reservation Time: 7:00 p.m.
Amazing Italian cuisine with a twist of originality. Choose from their extensive wine list that includes wines from around the world. Enjoy great food and great service surrounded by a modern and comfortable atmosphere.
Estimate $26–$60 CDN per person, plus taxes and 15% gratuity
www.mezzanotte-bistro.com

### CASUAL RESTAURANTS

**Blue Cactus Bar & Grill**
24 spots reserved
Reservation Time: 7:30 p.m.
A fun and casual dining experience surrounded by fresh, upscale Southwestern décor. Come and enjoy award-winning Margaritas and contemporary Southwestern cuisine.
Estimate $23–$51 CDN per person, plus taxes and 15% gratuity
www.bluecactusbarandgrill.com

**The Aulde Dubliner**
24 spots reserved
Reservation Time: 7:30 p.m.
Excellent modern Irish-rooted pub with a delicious mix of light and hearty fare. Located in the heart of the Byward Market, this restaurant features an expansive view overlooking the market. Come and enjoy the warm and friendly atmosphere. Offers a kids’ menu. Excellent beer selections.
Estimate $20–$40 CDN per person, plus taxes and 15% gratuity
www.auldedubliner.com
Milestones Restaurant & Bar
20 spots reserved
Reservation Time: 7:30 p.m.
Offers patrons innovative food, cocktails and great service. Surrounded by eclectic and relaxed décor—which is stylishly rich in wood and comfort. Signature drink is the “Bellini”—a definite must!
Estimate $31–$50 CDN per person, plus taxes and 15% gratuity
www.milestonesrestaurants.com

Metropolitan Brasserie
20 spots reserved
Reservation Time: 7:30 p.m.
Located in the heart of downtown, this Parisien style Brasserie offers guests both excellent cuisine and French Bistro decor. Exclusive oyster bar and extensive wine/cocktail list.
Estimate $25–$79 CDN per person, plus taxes and 15% gratuity for a three course meal.
www.metropolitainbrasserie.com

UPSCALE RESTAURANTS

e18hteen
24 spots reserved
Reservation Time: 7:00 p.m.
World-fusion cuisine in a beautifully restored historic building. Two-story high ceilings, fireplace and brick walls. Excellent food and wine.
Estimate $41–$62 CDN per person, plus taxes and 17% gratuity
www.restaurant18.com

Social
20 spots reserved
Reservation Time: 7:00 p.m.
Enjoy traditional French and contemporary North American cuisine within Social’s sumptuous and elegant atmosphere. With its distinctive architecture and interior décor, Social is a popular spot for local Ottawatonians. Great food and service.
Estimate $31–$57 CDN per person, plus taxes and 15% gratuity
www.social.ca
The following tours have been reserved for guests on Friday, September 8 and Saturday, September 9, 2006. Each tour group will be accompanied by a tour director who will meet the group in the lobby of the Westin Hotel prior to tour departure. Tour descriptions and times are listed below. Guests are encouraged to pre-register for the tours that they would like to participate in when they pre-register for the conference, as spots will go quickly. On-site tour registration will take place at the hotel on Wednesday, September 6 between 5:00 – 7:00 p.m. and Thursday, September 7 between 7:00 a.m. – 4:00 p.m. and will be on a first-come, first-served basis for any empty spots. Payments can be made on-site at the hotel for any tours that have not been pre-registered and paid for.

*Please note that prices include transportation, trip director and tour/activity costs. If minimum numbers are not met, tours will be cancelled.

FRIDAY, SEPTEMBER 8, 2006

Tour Option # 1:  Cordon Bleu Cooking Institute
Le Cordon Bleu Paris Culinary Arts Institute has evolved from a Parisian Culinary School, established in 1895, to an international culinary network with more than 26 schools in 15 countries. For more than a hundred years, people around the world have looked to Le Cordon Bleu for “la crème de la crème” in professional training in the culinary arts. If you love to cook and you love to eat, then this tour is for you. Join your host for a guided tour of the Culinary Institute, where you can see the chefs at work. Following your tour, you will be invited to observe a one-hour chocolate cooking demonstration by one of their in-house chefs. Everyone will be able to sample the results and even take home a few samples, too. Enjoy!

To learn more about the Cordon Bleu Cooking Institute, please visit their web site at www.cordonbleu.net.

Schedule:
9:00 a.m. Meet trip director in lobby of Westin Ottawa
9:10 a.m. Depart for Cordon Bleu
9:30 a.m. Tour and chocolate cooking demonstration
11:30 a.m. Re-board Bus for return transfer
11:45 a.m. Arrive back at Westin Ottawa

Length of Tour: 2 hours
Minimum # of Participants: 20 people
Maximum # of Participants: 40 people
Cost: $105 USD per person

Tour Option # 2:  Old English Trolley Guided City Tour
Climb aboard your very own Old English Trolley and enjoy a two-hour private tour of Ottawa. With the expert knowledge of your tour guide, you will be carried through the downtown core, along Confederation Boulevard (our ceremonial route), past monuments and many of Ottawa’s main attractions, including the Museum of Civilization, the National Gallery, Rideau Hall, the Supreme Court and much more. There will be plenty of opportunity for taking pictures.

To learn more about Ottawa, please visit the city’s web site at www.ottawa.ca.

Schedule:
9:30 a.m. Meet trip director in lobby of Westin Ottawa and board bus or trolley
9:45 a.m. Guided city tour begins
11:45 a.m. End of city tour, arrive back at Westin Ottawa

Length of Tour: 2 hours
Minimum # per tour: 10 people
Maximum # per tour: 30 people
Cost: $70 USD per person
Tour Option # 3: Walking Tour of Downtown and Byward Market

Accompanied by your very own historically costumed guide, guests will get a personal tour of the renowned Byward Market. Comprised of many historical buildings and unique shopping venues, the Byward Market is a wonderful place to explore. Your two-hour tour will include a short walk along the Rideau Canal, a brief stop at the Tomb of the Unknown Soldier, Parliament Hill, Majors Hill Park, the American Embassy and concluding in the Byward Market. Each participant will be given a Beavertail coupon for a Cinnamon and Sugar Beavertail (a “must try” for anyone visiting Ottawa).

*Please note, tour operates rain or shine, unless heavy thunderstorms. Please be prepared.

To learn more about Ottawa, please visit the city’s web site at www.ottawa.ca.

Schedule:
9:30 a.m. Meet trip director in lobby of Westin Ottawa
9:45 a.m. Depart on walking tour
11:30 a.m. Return to Westin Ottawa

Length of Tour: 2 hours
Minimum # per tour: 10 people
Maximum # per tour: 25 people
Cost: $40 USD per person

Tour Option # 2: Parliament Hill — Centre Block

A must see for every visitor to the Nation’s Capital, the Parliament buildings are rich in history, architecture and politics. Knowledgeable, bilingual tour guides will lead your group through the Centre Block, the House of Commons and the Senate, imparting information and answering any questions that the group may have. After the tour, participants are invited to visit the magnificent Peace Tower and travel to the top for a spectacular view of the city.

Schedule:
1:15 p.m. Meet trip director in lobby of Westin Ottawa and depart on foot
1:30 p.m. Arrive at Parliament Hill, check in with group tours
1:45 p.m. Private tour of Parliament Hill — Centre Block
2:30 p.m. End of tour, guests can visit the Peace Tower and the gift shop
2:50 p.m. Group departs for return to Westin Ottawa
3:00 p.m. Arrive back at Westin Ottawa

Length of Tour: 1 hour
Minimum # per tour: 10 people
Maximum # per tour: 50 people (recommend 25)
Cost: $15 USD per person

* Please note that, should the House be in session, tours will not operate. Cancellation of tours, due to official functions, could be of very short notice.

To learn more about Parliament Hill, please visit their web site at www.parl.gc.ca.

Tour Option # 1: Bicycle Tours

Bicycle tours are a great way to see Ottawa. Accompanied by a knowledgeable tour guide, you are bound to have fun exploring the city by bicycle while receiving a commentary. Two different guided tours are available: Rockcliffe Park (the only tour in Ottawa allowed to travel through this exclusive area) or the Rideau Canal. Mountain bicycles are available for all age groups. Tour route will be determined on the day of the event.

To learn more about Ottawa, please visit the city’s web site at www.ottawa.ca.

Schedule:
1:15 p.m. Meet trip director in lobby of Westin hotel and walk to bicycle tour location
1:30 p.m. Acquire bicycles and helmets and meet with their tour guide(s)
1:40 p.m. Depart on bicycle tour
3:00 p.m. Arrive back at start location, guests return all equipment and walk back to hotel

Length of Tour: 2 hours
Minimum # per tour: 10 people
Maximum # per tour: 30 people
Cost: $35 USD per person (includes fitting/adjustment, bike, helmet, lock and map)
Social Event Information

Friday, September 8, 2006

Canadian War Museum
7:00 – 11:00 p.m.

Welcome to Ottawa’s newest museum, the Canadian War Museum. This museum is a culmination of many minds and is a tribute to all of our citizens who ever participated in a war. Designed to look like a bunker from the outside, the Canadian War Museum offers a number of fascinating exhibits inside that will truly tell the tale of the wars fought and won...and lost. In addition to entertainment, the Museum exhibits will be opened for guests to wander through on self-guided tours throughout the evening, with Museum guides located in each of the four exhibit sections to answer any questions that you may have.

Tonight, come and spend a fun night in your exclusive 1940’s “Officer’s Club.” From delicious food, great ambiance and excellent entertainment, tonight is sure to be a night to remember! Relax with your colleagues on comfortable couches and Boogie Woogie with a real swing band. Eat at leisure at the mouth-watering buffet stations. Sizzle up to the bar for a taste of 1940s cocktails. And explore the many vehicles of war in the numerous displays throughout the Lebreton Gallery. It is all here for you to enjoy!

Costumes are optional and can be rented on-site, if desired. Or...if you were a member of the armed services of either Canada or the United States, pull out your old uniform, polish off your medals, head out to the dance floor and do the jitterbug, the shim sham or the lindy hop!

Costume Details

For the Officer’s Club evening at the Canadian War Museum on Friday, September 8, 2006, any of your guests who would like to have a costume for the evening have a few options to choose from:

1) Bring their own costume with them
2) Pre-order a costume and/or accessories prior to arrival in Ottawa—best option
3) Order a costume and/or accessories on-site upon arrival (Please note that this option will not guarantee that a costume or accessories will be available)

A Bit of Background on the 1940’s Clothing Era...

During this time, both men and women were smaller than they are today. As such, many of the vintage costumes from the 1940s (e.g., military dress, women’s ballgowns) are only available in smaller sizes for both men and women. However, costumes that are not vintage era, but are representative of the 1940s, especially when matched with the appropriate accessories, are available in many different sizes.

Popular dress during this time included military uniforms, zoot suits, tuxedos with tails, women’s long ballgowns and the shorter knee-length skirt/jacket/blouse and/or pants for women. Small hats, sequined bags, fedoras, boas, etc. were also used to dress up the outfit.

Fun Night

For those guests who would like to have a costume and/or accessories for this event, we have a number of options to choose from:

**Men:**
- zoot suits (green, navy, charcoal or blue)
- fedoras, pocket watches (rented individually)
- accessory package (Fedora, white tie, black shirt @ $30 CDN + GST each)
- vintage military dress (will fit smaller men only)
- military dress (not specific to 1940s era)
- tuxedos with tails

**Women:**
- vintage ballgowns (will fit smaller women only)
- ballgowns
- lady’s suits
- boas, tiaras, long gloves, hats, purses (rented individually)
- accessory package (boa, tiara, long gloves @ $30 CDN + GST each)

If guests order a costume, accessories are included. However, they also have the option of just ordering the accessories (individually or as a package) to augment their own outfit.

**Cost:**

The cost for each costume ranges from $75 CDN and upwards, depending upon the costume that is rented and whether or not it is vintage. If guests have a budget, the costume house will be able to put something together for them within their budget.

**Notes:**

1) In order to ensure the best possibility of costume availability, guests will need to pre-order their costumes. This can be done directly through Delightful Fancies & Treasures. Phone: 613 238-2058 or e-mail: delightfulfancies@netscape.net

Contact Person: Aimée. There will be no guarantee of availability of costumes. They will be rented on a first come, first served basis.

2) All costumes will be delivered to the hotel the morning of Friday, September 8, 2006 and picked up from the hotel as of 10:00 a.m., Saturday, September 9, 2006. Guests will need to ensure that all costumes are returned to the registration desk prior to 9:30 a.m. on Saturday, September 9.

3) Guests will be invoiced directly for the costume rental by Delightful Fancies & Treasures. They accept Visa, MasterCard, AMEX, Interac and cash.

A representative from the costume house can be on-site during part of the registration hours on September 6 and 7 and will be able to take last minute orders and have sample costumes on-site for guests to see.

NOTE: Drinking age at the Canadian War Museum is 19 years. There will be no exceptions.

To learn more about the Canadian War Museum, please visit their web site at www.warmuseum.ca.

Register on Line at www.auanet.org/northeastern/
SATURDAY, SEPTEMBER 9, 2006

5K Fun Run
6:15 – 9:00 a.m.

Rideau Canal

For those avid joggers and runners, this morning is for you! Come and join your colleagues on an early morning Fun Run along the banks of the Rideau Canal. Please pick up your race packages from the registration desk upon arrival at the conference. Prizes will be given to the top three male and female runners. Race begins promptly at 7:00 a.m. for runners; 7:10 a.m. for walkers.

To learn more about the Rideau Canal, please visit www.ottawa.ca. You will find information about the Rideau Canal under “Attractions” under the Visiting Ottawa drop down menu.

Tennis
1:15 – 4:30 p.m.

THE OTTAWA ATHLETIC CLUB

The Ottawa Athletic Club is a wonderful facility that plays host to both indoor and outdoor tennis courts—some of the nicest in the city. This afternoon, you will participate in a tennis game. Rackets and tennis balls can be rented. Transportation is on your own. Tennis courts have been reserved.

Schedule:
1:15 p.m. Meet trip director in lobby of Westin Hotel
1:30 p.m. Depart hotel for Ottawa Athletic Club via taxi (transportation costs not included)
1:45 p.m. Arrive at club
2:00 p.m. Game begins
4:00 p.m. Game ends
4:15 p.m. Depart Ottawa Athletic Club and return to hotel
4:30 p.m. Arrive back at Westin hotel

To learn more about the Ottawa Athletic Club, please visit their web site at www.ottawaathleticclub.com.

Golf Tournament
12:30 – 5:30 p.m.

CHATEAU CARTIER RESORT

This afternoon, guests are invited to participate in a golf tournament at one of Ottawa’s most beautiful golf courses, nestled along the banks of the Ottawa River. Foursomes will tee off back to back, with nine-minute intervals. Tee off times will be allocated on a first-come, first-served basis. Please indicate on your registration form your handicap and who you would like to golf with; otherwise, we will create the foursomes. Prizes will be given out for a number of different competitions; including closest to the pin, best overall score (male and female), longest drive and longest putt.

Guests are invited to bring their own golf clubs or to rent from the golf course (please indicate if you require right- or left-handed clubs). Electric carts will also be provided for every pair of golfers.

Please pick up your information packages for the golf tournament from the registration desk when you arrive for the conference.

Note: For those guests who are bringing their golf clubs, your clubs will be transported to the golf course between 8:30 – 10:00 a.m. on Saturday, September 9. As such, all golf clubs must be tagged with your name when they are dropped off. Tags will be provided for those who do not have a name tag for their golf bag.

To learn more about the Chateau Cartier Resort and Golf Course, please visit their web site at www.chateaucartier.com.
President’s Banquet

Join Us for an Evening of Jest
Listen to the unique and humorous
Mr. Daniel Richer—Town Crier and Actor
Saturday, September 9, 2006

Reception at 7:00 p.m.
Banquet at 8:00 p.m.
Program and Awards 8:00 p.m.

In the Confederation Ballroom
here at the Westin Hotel
Ottawa, Ontario, Canada

Semi-formal attire

Note: If you have registered for the
NS-ALIA’s 2006 Annual Meeting you
will receive one complimentary ticket.
Additional tickets are $75 and can
be purchased at the Registration
Desk. Children under 19 are
not permitted.

REGISTER ON LINE AT WWW.AUANET.ORG/NORTHEASTERN/
# EXHIBITOR LISTING (ALPHA)

<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Abbott Laboratories</strong></td>
<td>311</td>
</tr>
<tr>
<td>8401 TransCanada Highway</td>
<td></td>
</tr>
<tr>
<td>St. Laurent PQ H4S 1Z1 Canada</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.abbott.com">www.abbott.com</a></td>
<td></td>
</tr>
<tr>
<td><strong>American Kidney Stone Management, Ltd.</strong></td>
<td>307</td>
</tr>
<tr>
<td>100 W. Third Avenue, Suite 350</td>
<td></td>
</tr>
<tr>
<td>Columbus, OH 43201</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.aksm.com">www.aksm.com</a></td>
<td></td>
</tr>
<tr>
<td><strong>Auxilium Pharmaceuticals, Inc.</strong></td>
<td>502</td>
</tr>
<tr>
<td>40 Valley Stream Parkway</td>
<td></td>
</tr>
<tr>
<td>Malvern, PA 19355</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.auxilium.com">www.auxilium.com</a></td>
<td></td>
</tr>
<tr>
<td><strong>American Medical Systems</strong></td>
<td>304</td>
</tr>
<tr>
<td>10700 Bren Road West</td>
<td></td>
</tr>
<tr>
<td>Minnetonka, MN 55343</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.AmericanMedicalSystems.com">www.AmericanMedicalSystems.com</a></td>
<td></td>
</tr>
<tr>
<td>American Medical Systems is a world leader in medical devices and procedures that treat three major diseases: incontinence, erectile dysfunction and benign prostate hyperplasia. Any one of these conditions can profoundly diminish a patient’s quality of life and significantly impact relationships. Our products provide a cure or reduce the incapacitating effects of these diseases, often through minimally invasive surgery.</td>
<td></td>
</tr>
<tr>
<td><strong>Astellas Pharma US, Inc.</strong></td>
<td>102</td>
</tr>
<tr>
<td>Three Parkway North</td>
<td></td>
</tr>
<tr>
<td>Deerfield, IL 60015</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.us.astellas.com">www.us.astellas.com</a></td>
<td></td>
</tr>
<tr>
<td>VESiCare® (solifenacin succinate) is a competitive muscarinic receptor antagonist and is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.</td>
<td></td>
</tr>
<tr>
<td><strong>Aureon Laboratories</strong></td>
<td>209</td>
</tr>
<tr>
<td>28 Wells Avenue</td>
<td></td>
</tr>
<tr>
<td>Yonders, NY 1070</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.prostatepx.com">www.prostatepx.com</a></td>
<td></td>
</tr>
<tr>
<td>Aureon Laboratories’ Prostate Px™ for prostatectomy tissue and Prostate Px™ utilizing biopsy samples stratify patient risk and predict disease severity. Aureon’s Systems Pathology platform integrates histology, molecular markers, clinical features, advanced image analysis and mathematics to provide a personalized report for the risk of prostate cancer recurrence.</td>
<td></td>
</tr>
<tr>
<td><strong>Bayer Healthcare Corporation</strong></td>
<td>303</td>
</tr>
<tr>
<td>400 Morgan Lane</td>
<td></td>
</tr>
<tr>
<td>West Haven, CT 06516</td>
<td></td>
</tr>
<tr>
<td><a href="http://www.bayerusa.com">www.bayerusa.com</a></td>
<td></td>
</tr>
<tr>
<td>Bayer Healthcare Corporation invites you to visit our booth where our medical representatives can discuss our full range of healthcare products including VIADUR™ (leuprolide acetate implant), Bayer Oncology and NEXAVAR (sorafenib) tablets.</td>
<td></td>
</tr>
</tbody>
</table>

Boehringer Ingelheim Pharma, Inc. is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 152 affiliates in 45 countries and more than 34,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. Please visit our exhibit to discuss the latest clinical information on: Flomax® (tamsulosin hydrochloride)

**Boston Scientific Corporation** 504
100 Boston Scientific Way
Marlborough, MA 01752
www.bostonscientific.com

**Cook Urological** 107
1100 West Morgan Street
Spencer, IN 47460
www.cookurological.com

A recognized leader worldwide, Cook Urological develops and manufactures products for endourology, ureteroscopy and incontinence management/treatment. Product lines include: ureteral stents and catheters, stone manipulation devices, dilators and access sheaths, wire guides and urethral slings.

The latest product innovations include: Stratasis® TF Tension Free Urethral Sling, for surgical treatment of SUI, Flexor® Ureteral Access Sheath, NCompass® Nitinol Stone extractors, and the Ascend™ Ureteral Balloon Dilator.

**Dendreon Corporation** 112
3005 1st Avenue
Seattle, WA 98121
www.dendreon.com

**DiagnoCure Inc.** 306
2050 W. Rene-Levesque Boulevard West, 6th Floor
Saint-Foy QE G1V 2K8 Canada
www.diagnocure.com

**Dornier MedTech** 105
1155 Roberts Boulevard
Kennesaw, GA 30144
www.dornier.com
<table>
<thead>
<tr>
<th>Company</th>
<th>Booth No.</th>
<th>Company Booth No.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EDAP-TMS</strong></td>
<td>411</td>
<td><strong>HealthTronics, Inc.</strong> 206</td>
</tr>
<tr>
<td>4 rue du Dauphine</td>
<td></td>
<td>1301 Capital of Texas Highway, Suite 200B Austin, TX 78746 <a href="http://www.healthtronics.com">www.healthtronics.com</a></td>
</tr>
<tr>
<td>69120 Vaulx-en-Velin, France</td>
<td></td>
<td>HealthTronics is a urological products and services company that offers a comprehensive range of diagnostic and therapeutic solutions to physicians, hospitals, surgery centers and clinics. HealthTronics offers the latest technology in lithotripsy services and prostate therapy services. Its product portfolio includes lithotripters, intra-operative imaging systems, surgical lasers for treatment of BPH, urology imaging tables and anatomical pathology services.</td>
</tr>
<tr>
<td><a href="http://www.edap-tms.com">www.edap-tms.com</a></td>
<td></td>
<td><strong>Interstitial Cystitis Association</strong> 412</td>
</tr>
<tr>
<td><strong>Endocare, Inc.</strong></td>
<td>410</td>
<td>110 North Washington Street, Suite 340 Rockville, MD 20850 <a href="http://www.ichelp.org">www.ichelp.org</a></td>
</tr>
<tr>
<td>201 Technology Drive</td>
<td></td>
<td>Founded by Dr. Vicki Ratner in 1984 the ICA is dedicated to providing comprehensive, current information on interstitial cystitis (IC), supporting IC patients, families, &amp; friends; educating the medical community and public about IC; advocating for research funding and patients’ rights; and promoting &amp; providing research funding for treatments and a cure for IC.</td>
</tr>
<tr>
<td>Irvine, CA 92618</td>
<td></td>
<td><strong>Intuitive Surgical</strong> 402</td>
</tr>
<tr>
<td><a href="http://www.endocare.com">www.endocare.com</a></td>
<td></td>
<td>1266 Kifer Road, Building 101 Sunnyvale, CA 94086 <a href="http://www.intuitivesurgical.com">www.intuitivesurgical.com</a></td>
</tr>
<tr>
<td><strong>Esprit Pharma, Inc.</strong></td>
<td>103/202</td>
<td>Intuitive Surgical, Inc. is shaping the future of urologic oncology surgery with the da Vinci® Prostatectomy (dVP). dVP represents the fastest growing treatment for prostate cancer today and leverages the da Vinci Surgical System’s state-of-the-art technology, including high resolution 3D vision, proprietary EndoWrist® instrumentation, Intuitive Motion and 4th arm.</td>
</tr>
<tr>
<td>Two Tower Center Boulevard</td>
<td></td>
<td><strong>Karl Storz Lithotripsy-America, Inc.</strong> 403</td>
</tr>
<tr>
<td>East Brunswick, NJ 08816</td>
<td></td>
<td>1000 Cobb Place Boulevard, Building 400, Suite 450 Kennesee, GA 30144 <a href="http://www.karlstorz.com">www.karlstorz.com</a></td>
</tr>
<tr>
<td><a href="http://www.espiritpharma.com">www.espiritpharma.com</a></td>
<td></td>
<td>The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well as a diagnostic and therapeutic workstation. Equipped with patented, electromagnetic shock wave technology, offering selectable focus as well as in-line ultrasound and X-ray localization capabilities, the F2 provides unparalleled reliability and precision in treatment. With more than 700 various systems operating worldwide, Karl Storz Lithotripsy - America, Inc. provides nationwide sales and customer support, service technicians and applications training, plus financing and leasing options.</td>
</tr>
<tr>
<td><strong>GE Health Care</strong></td>
<td>408</td>
<td><strong>Intercontinental</strong></td>
</tr>
<tr>
<td>384 Wright Brothers Drive</td>
<td></td>
<td><strong>Karl Storz Lithotripsy-America, Inc.</strong> 403</td>
</tr>
<tr>
<td>Salt Lake City, UT 84116</td>
<td></td>
<td>1000 Cobb Place Boulevard, Building 400, Suite 450 Kennesee, GA 30144 <a href="http://www.karlstorz.com">www.karlstorz.com</a></td>
</tr>
<tr>
<td><a href="http://www.gehealthcare.com">www.gehealthcare.com</a></td>
<td></td>
<td>The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well as a diagnostic and therapeutic workstation. Equipped with patented, electromagnetic shock wave technology, offering selectable focus as well as in-line ultrasound and X-ray localization capabilities, the F2 provides unparalleled reliability and precision in treatment. With more than 700 various systems operating worldwide, Karl Storz Lithotripsy - America, Inc. provides nationwide sales and customer support, service technicians and applications training, plus financing and leasing options.</td>
</tr>
<tr>
<td><strong>GlaxoSmithKline Canada</strong></td>
<td>204</td>
<td><strong>Karl Storz Lithotripsy-America, Inc.</strong> 403</td>
</tr>
<tr>
<td>8455 Transcanadienne</td>
<td></td>
<td>1000 Cobb Place Boulevard, Building 400, Suite 450 Kennesee, GA 30144 <a href="http://www.karlstorz.com">www.karlstorz.com</a></td>
</tr>
<tr>
<td>St. Laurent, QE H4S 1Z2 Canada</td>
<td></td>
<td>The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well as a diagnostic and therapeutic workstation. Equipped with patented, electromagnetic shock wave technology, offering selectable focus as well as in-line ultrasound and X-ray localization capabilities, the F2 provides unparalleled reliability and precision in treatment. With more than 700 various systems operating worldwide, Karl Storz Lithotripsy - America, Inc. provides nationwide sales and customer support, service technicians and applications training, plus financing and leasing options.</td>
</tr>
<tr>
<td><a href="http://www.gsk.ca">www.gsk.ca</a></td>
<td></td>
<td><strong>Karl Storz Lithotripsy-America, Inc.</strong> 403</td>
</tr>
<tr>
<td><strong>Gyrus ACMI</strong></td>
<td>213</td>
<td>1000 Cobb Place Boulevard, Building 400, Suite 450 Kennesee, GA 30144 <a href="http://www.karlstorz.com">www.karlstorz.com</a></td>
</tr>
<tr>
<td>136 Turnpike Road</td>
<td></td>
<td>The Storz MODULITH® SLX-F2 is a one-of-a-kind lithotripter as well as a diagnostic and therapeutic workstation. Equipped with patented, electromagnetic shock wave technology, offering selectable focus as well as in-line ultrasound and X-ray localization capabilities, the F2 provides unparalleled reliability and precision in treatment. With more than 700 various systems operating worldwide, Karl Storz Lithotripsy - America, Inc. provides nationwide sales and customer support, service technicians and applications training, plus financing and leasing options.</td>
</tr>
<tr>
<td>Southborough, MA 01772</td>
<td></td>
<td><strong>Karl Storz Lithotripsy-America, Inc.</strong> 403</td>
</tr>
<tr>
<td><a href="http://www.GyrusACMI.com">www.GyrusACMI.com</a></td>
<td></td>
<td>1000 Cobb Place Boulevard, Building 400, Suite 450 Kennesee, GA 30144 <a href="http://www.karlstorz.com">www.karlstorz.com</a></td>
</tr>
<tr>
<td>Gyrus ACMI is uniquely positioned to offer physicians complete “see &amp; treat” solutions including capital equipment, comprehensive disposables and service plans that support their clinical goals and financial challenges.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Company</td>
<td>Booth No.</td>
<td></td>
</tr>
<tr>
<td>------------------------------------------------------------------------</td>
<td>-----------</td>
<td></td>
</tr>
<tr>
<td>Karl Storz Endoscopy-America, Inc</td>
<td>403</td>
<td></td>
</tr>
<tr>
<td>600 Corporate Pointe</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Culver City, CA 90230</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.karlstorz.com">www.karlstorz.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>An international leader in the field of endoscopy for over 60 years,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karl Storz designs, engineers, and manufactures full lines of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>instrumentation for minimally invasive adult and pediatric urology,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>endourology and laparoscopic urologic procedures. With our superior</td>
<td></td>
<td></td>
</tr>
<tr>
<td>product line breadth, innovative craftsmanship and clinical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>effectiveness, we continue our commitment to advancing endoscopic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>technology.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laborie Medical</td>
<td>111</td>
<td></td>
</tr>
<tr>
<td>185 Allen Brook Lane</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Williston, VT 05495</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.laborie.com">www.laborie.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urodynamics in now Wireless! Laborie UDS systems for pelvic floor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dysfunction diagnosis and therapy has made urodynamics easier and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>faster to perform with wireless technology and air-charged catheters.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laborie’s family of products: Delphis™, Wireless, 8+ channel</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urodynamics system, Triton™ Advanced Wireless UDS system ideal for the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>higher volume practice-expandable to Video, Aquarius TT™ the premier</td>
<td></td>
<td></td>
</tr>
<tr>
<td>wireless urodynamics system, Urostym™ a comprehensive stimulation/biofeed-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>back treatment system and i-LIST™, information technology integration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>solutions to streamline your data process.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lakewood Pathology Associates (LPA)</td>
<td>409</td>
<td></td>
</tr>
<tr>
<td>1200 River Avenue, Building 10E</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lakewood, NJ 08701</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.lakewoodpath.com">www.lakewoodpath.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A full service, national pathology company, LPA provides anatomical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pathology services tailored to the outpatient needs of Urologists.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Our facility is accredited by the College of American Pathologists</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with distinction for exceptional service and quality, consistently</td>
<td></td>
<td></td>
</tr>
<tr>
<td>turning around pathology reports in 48–72 hours interpreted by</td>
<td></td>
<td></td>
</tr>
<tr>
<td>experienced, board certified pathologists.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laserscope</td>
<td>310</td>
<td></td>
</tr>
<tr>
<td>3070 Orchard Drive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>San Jose, CA 95134</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.laserscope.com">www.laserscope.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liebel Flarsheim</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>2111 East Galbraith Road</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cincinnati, OH 45215</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.liebel.com">www.liebel.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liebel Flarsheim manufactures urology imaging systems, including the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>filmless digital Hydra Vision® DR with optimal geometry, extended</td>
<td></td>
<td></td>
</tr>
<tr>
<td>anatomical coverage, and LCD viewing with two 19” color monitors.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>These LCD color monitors come standard with Integrated Video</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Distribution. We offer the Hydra Vision® Plus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with Digital Photo Spot and film capability.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumenis</td>
<td>506</td>
<td></td>
</tr>
<tr>
<td>2400 Condensa Street</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santa Clara, CA 95051</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.lumenis.com">www.lumenis.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumenis® Inc. is the global leader in medical and aesthetic lasers and</td>
<td></td>
<td></td>
</tr>
<tr>
<td>light-based technology offering multipurpose laser systems used for</td>
<td></td>
<td></td>
</tr>
<tr>
<td>stones, strictures, tumors and BPH treatment. Holmium ablation of the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prostate is a simple-to-learn outpatient procedure. It’s easy to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>become an expert with this highly effective technique that eliminates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>traditional complications associated with TURP Holmium ablation of the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>prostate. Patients experience immediate symptom relief, little if</td>
<td></td>
<td></td>
</tr>
<tr>
<td>any bleeding and may be released the same day without a catheter.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holmium technology provides minimum penetration with maximum results.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The superficial penetration of holmium ensures that tissue is</td>
<td></td>
<td></td>
</tr>
<tr>
<td>efficiently vaporized and eliminates concern about damage to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>surrounding tissue. Holmium ablation is the cost effective solution.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hospitals gain unmatched economic benefits by utilizing the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>multipurpose holmium laser.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maple Leaf Hifu</td>
<td>106</td>
<td></td>
</tr>
<tr>
<td>1377 Cormorant Road, #203</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ancaster, Ontario L9G 4V5 Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.hifu.ca">www.hifu.ca</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medispec, Ltd.</td>
<td>407</td>
<td></td>
</tr>
<tr>
<td>12850 Middlebrook Road, Suite 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germantown, MD 20874</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.medispec.com">www.medispec.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medispec is a leading supplier of affordable shock wave technology to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the worldwide medical community. The modular E3000 Lithotripsy System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>is easy-to-use and highly effective at breaking stones. Medispec’s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>excellent products and best-in-class business solutions give your</td>
<td></td>
<td></td>
</tr>
<tr>
<td>patients access to quality care while making a sound investment in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>your future.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medtronic</td>
<td>109</td>
<td></td>
</tr>
<tr>
<td>710 Medtronic Parkway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Minneapolis, MN 55432</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.medtronic.com">www.medtronic.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medtronic, the global leader in medical technology, introduces the</td>
<td></td>
<td></td>
</tr>
<tr>
<td>InterStim® II system for urinary control and PROSTIVA™ RF Therapy.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Consider InterStim® Therapy, an effective treatment option for your</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OAB patients. Choose PROSTIVA® RF Therapy – precise, proven RF</td>
<td></td>
<td></td>
</tr>
<tr>
<td>technology to treat your patients with symptoms of BPH.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mentor Corp.</td>
<td>305</td>
<td></td>
</tr>
<tr>
<td>201 Mentor Drive</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Santa Barbara, CA 93777</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.mentorcorp.com">www.mentorcorp.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mentor is a leading global manufacturer and marketer of innovative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medical devices and disposable products for the diagnosis, management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>and treatment of urological disorders to include incontinence,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>retention, prostate and bladder cancer, stone management and erectile</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dysfunction.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Company</td>
<td>Booth No.</td>
<td>Company</td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>-----------</td>
<td>-----------------------------------------------------</td>
</tr>
<tr>
<td>Merck Frosst Canada LTD.</td>
<td>207</td>
<td>Q-Med Scandinavia, Inc.</td>
</tr>
<tr>
<td>40 Cramer Drive, Nepean, ON K2H 5X5 Canada</td>
<td></td>
<td>103 Carnegie Center, Suite 301, Princeton, NJ 08540</td>
</tr>
<tr>
<td><a href="http://www.merckfrosst.ca">www.merckfrosst.ca</a></td>
<td></td>
<td><a href="http://www.q-med.com">www.q-med.com</a></td>
</tr>
<tr>
<td>Novartis Pharmaceuticals — Oncology Division</td>
<td>108</td>
<td>Qualigen, Inc.</td>
</tr>
<tr>
<td>180 Park Avenue, Fordham Park, NJ 07932</td>
<td></td>
<td>2042 Corte del Nogal, Suite B, Carlsbad, CA 92011</td>
</tr>
<tr>
<td><a href="http://www.novartis.com">www.novartis.com</a></td>
<td></td>
<td><a href="http://www.qualigeninc.com">www.qualigeninc.com</a></td>
</tr>
<tr>
<td>Novartis Oncology is dedicated to innovative</td>
<td></td>
<td>Qualigen, Inc. develops, manufactures and</td>
</tr>
<tr>
<td>approaches, practical solutions and valuable</td>
<td></td>
<td>distributes the FastPack® System which is the</td>
</tr>
<tr>
<td>medical therapies that satisfy the current</td>
<td></td>
<td>first blood testing analyzer designed to</td>
</tr>
<tr>
<td>and emerging needs of patients with cancer and the</td>
<td></td>
<td>perform quantitative immunoassay tests right in</td>
</tr>
<tr>
<td>health care professionals who care for them.</td>
<td></td>
<td>the physician’s office. Utilizing the FastPack®</td>
</tr>
<tr>
<td>Come visit our exhibit.</td>
<td></td>
<td>System, physicians can obtain on-demand</td>
</tr>
<tr>
<td></td>
<td></td>
<td>laboratory-quality immunoassay test results for</td>
</tr>
<tr>
<td></td>
<td></td>
<td>their patients in minutes for PSA, TSH and freeT4.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olympus Surgical America</td>
<td>210</td>
<td>Richard Wolf Medical Instruments Corporation</td>
</tr>
<tr>
<td>One Corporate Drive, Orangeburg, NY 10962</td>
<td></td>
<td>353 Corporate Woods Parkway, Vernon Hills, IL</td>
</tr>
<tr>
<td><a href="http://www.olympussurgical.com">www.olympussurgical.com</a></td>
<td></td>
<td>60616</td>
</tr>
<tr>
<td>Olympus Surgical America is excited to introduce</td>
<td></td>
<td><a href="http://www.richardwolfusa.com">www.richardwolfusa.com</a></td>
</tr>
<tr>
<td>the following new and unique products: EXERA II™</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Universal Platform High Definition video system</td>
<td></td>
<td></td>
</tr>
<tr>
<td>with our HD EndoEYE line of video laparoscopes,</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYF-V2 Flexible Video Cystoscope, URF-P5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flexible Ureteroscope, Video Ureteroscope, OES Pro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ureteroscopes, Percutaneous Nephroscope, Resection-in-Saline</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resectoscope, and new Bipolar Laparoscopic forcepts.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncura</td>
<td>208</td>
<td>sanofi-aventis</td>
</tr>
<tr>
<td>301 Plymouth Road, Suite 130, Plymouth Meeting, PA</td>
<td></td>
<td>300 Sumerset Corporate Bridgewater, NJ 08807</td>
</tr>
<tr>
<td>19462</td>
<td></td>
<td><a href="http://www.sanofi-aventis.com">www.sanofi-aventis.com</a></td>
</tr>
<tr>
<td><a href="http://www.oncura.com">www.oncura.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer</td>
<td>212</td>
<td></td>
</tr>
<tr>
<td>235 E. 42nd Street, New York, NY 10017</td>
<td></td>
<td></td>
</tr>
<tr>
<td><a href="http://www.pfizer.com">www.pfizer.com</a></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acting on Our Commitment to Urology.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prescription Dispensing Labs</td>
<td>205</td>
<td>TAP Pharmaceuticals Inc. is a joint venture of</td>
</tr>
<tr>
<td>19230 Stone Oak Parkway, Suite 200, San Antonio,</td>
<td></td>
<td>Abbott and Takeda Pharmaceutical Company Limited of</td>
</tr>
<tr>
<td>TX 78258</td>
<td></td>
<td>Japan. The sanofi-aventis Group is the world’s</td>
</tr>
<tr>
<td><a href="http://www.pdlabs.net">www.pdlabs.net</a></td>
<td></td>
<td>third largest pharmaceutical company, ranking</td>
</tr>
<tr>
<td></td>
<td></td>
<td>number one in Europe. Backed by a world-class</td>
</tr>
<tr>
<td></td>
<td></td>
<td>R&amp;D organization, sanofi-aventis is developing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>leading positions in seven major therapeutic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>areas: cardiovascular, thrombosis, oncology,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>metabolic diseases, central nervous system,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>internal medicine, and vaccines.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The sanofi-aventis Group is listed in Paris</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(EURONEXT: SAN) and in New York (NYSE: SNY).</td>
</tr>
<tr>
<td>PriCare</td>
<td>113</td>
<td>TAP Pharmaceuticals</td>
</tr>
<tr>
<td>Ortho McNeil, Inc., 600 Main #1003, Buffalo, NY</td>
<td></td>
<td>675 North Field Drive, Lake Forest, IL 60045</td>
</tr>
<tr>
<td>14202</td>
<td></td>
<td><a href="http://www.tap.com">www.tap.com</a></td>
</tr>
<tr>
<td><a href="http://www.levaquin.com">www.levaquin.com</a></td>
<td></td>
<td>TAP Pharmaceuticals Inc. is a joint venture of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abbott and Takeda Pharmaceutical Company Limited of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Japan.</td>
</tr>
<tr>
<td>United Medical Systems</td>
<td>308</td>
<td></td>
</tr>
<tr>
<td>1500 West Park Drive, Suite 390, Westborough, MA</td>
<td></td>
<td>United Medical Systems</td>
</tr>
<tr>
<td>01581</td>
<td></td>
<td>308</td>
</tr>
<tr>
<td><a href="http://www.ums-usa.com">www.ums-usa.com</a></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

REGISTER ON LINE AT WWW.AUANET.ORG/NORTHEASTERN/
**Company**  
**Urologix**  
14405 Twenty-First Avenue North  
Minneapolis, MN 55447  
www.urologix.com

**Uropath, LLC**  
3939 Green Oaks Boulevard Northeast, Suite 100  
Arlington, TX 75063  
www.uropathllc.com

**Valera Pharmaceuticals**  
7 Clarke Drive  
Canbury, NJ 08512  
www.valerapharma.com

Valera Pharmaceuticals is a specialty pharmaceutical company with an expertise in drug delivery. Valera’s technology is based on small, flexible polymer implants that release drugs using simple diffusion delivery for up to 12 months. An implant can be inserted in the body, utilizing a simple in-office procedure. Please visit our booth to see placebo filled versions of the implant.

**Company**  
**Watson Pharma, Inc.**  
360 Mt. Kemble Avenue  
Morristown, NJ 07962  
www.watsonpharm.com

Watson Pharma, Inc. is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson strives to be a leader in the area of urological disorders with the promotion of products for overactive bladder, prostate cancer and testosterone deficiency.

---

**Northeastern Section of the American Urological Annual Meeting**  
**September 7 - 9, 2006**  
Ottawa Westin  
Confederation 2-3 Rooms

**Exhibit Hall Hours**  
**Thursday, September 7, 2006**  
11:30 a.m.–1:00 p.m.  
5:30–7:00 p.m.

**Friday, September 8, 2006**  
10:00 a.m.–3:00 p.m.

**Saturday, September 9, 2006**  
9:00 a.m.–12:00 p.m.
### EXHIBITOR BY BOOTH NUMBER

<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Company</th>
<th>Booth No.</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>102</td>
<td>Astellas Pharma US Inc.</td>
<td>307</td>
<td>American Kidney Stone Management, Ltd.</td>
</tr>
<tr>
<td>103/202</td>
<td>Esprit Pharma, Inc.</td>
<td>308</td>
<td>United Medical Systems</td>
</tr>
<tr>
<td>104</td>
<td>Urologix</td>
<td>309</td>
<td>Uropath, LLC</td>
</tr>
<tr>
<td>105</td>
<td>Dornier MedTech</td>
<td>310</td>
<td>Laserscope</td>
</tr>
<tr>
<td>106</td>
<td>Maple Leaf Hifu</td>
<td>311</td>
<td>Abbott Laboratories</td>
</tr>
<tr>
<td>107</td>
<td>Cook Urological</td>
<td>312</td>
<td>Boehringer Ingelheim Pharma, Inc.</td>
</tr>
<tr>
<td>108</td>
<td>Novartis</td>
<td>313</td>
<td>Watson Pharma, Inc.</td>
</tr>
<tr>
<td>109</td>
<td>Medtronic</td>
<td>402</td>
<td>Intuitive Surgical</td>
</tr>
<tr>
<td>110</td>
<td>Liebel Flarsheim</td>
<td>403</td>
<td>Karl Storz Lithotripsy-America, Inc.,</td>
</tr>
<tr>
<td>111</td>
<td>Laborie Medical</td>
<td>403</td>
<td>Karl Storz Endoscopy-America, Inc</td>
</tr>
<tr>
<td>112</td>
<td>Dendreon Corporation</td>
<td>404</td>
<td>Q-Med Scandinavia, Inc.</td>
</tr>
<tr>
<td>113</td>
<td>PriCare</td>
<td>405</td>
<td>Valera Pharmaceuticals</td>
</tr>
<tr>
<td>203/302</td>
<td>sanofi-aventis</td>
<td>406</td>
<td>Qualigen, Inc.</td>
</tr>
<tr>
<td>204</td>
<td>GlaxoSmithKline Canada</td>
<td>407</td>
<td>Medispec, Ltd.</td>
</tr>
<tr>
<td>205</td>
<td>Prescription Dispensing Labs</td>
<td>408</td>
<td>GE Health Care</td>
</tr>
<tr>
<td>206</td>
<td>HealthTrronics</td>
<td>409</td>
<td>Lakewood Paathology Associates</td>
</tr>
<tr>
<td>207</td>
<td>Merck Frosst Canada LTD.</td>
<td>410</td>
<td>Endocare, Inc.</td>
</tr>
<tr>
<td>208</td>
<td>Oncura</td>
<td>411</td>
<td>EDAP-TMS</td>
</tr>
<tr>
<td>209</td>
<td>Aureon Laboratories</td>
<td>412</td>
<td>Interstitial Cystitis Association</td>
</tr>
<tr>
<td>210</td>
<td>Olympus Surgical America</td>
<td>413</td>
<td>TAP Pharmaceuticals</td>
</tr>
<tr>
<td>211</td>
<td>Richard Wolf Medical Instruments Corp.</td>
<td>502</td>
<td>Auxilium Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>212</td>
<td>Pfizer</td>
<td>504</td>
<td>Boston Scientific Corporation</td>
</tr>
<tr>
<td>213</td>
<td>Gyrus ACMI</td>
<td>506</td>
<td>Lumenis</td>
</tr>
<tr>
<td>303</td>
<td>Bayer Healthcare Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>304</td>
<td>American Medical Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>305</td>
<td>Mentor Corp.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>306</td>
<td>DiagnoCure Inc.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**You don’t want to miss this!**

Make sure to complete the raffle tickets included in your registration packet with your name and contact information. Prizes include complimentary registration to next year’s Annual Meeting in Rochester or a weekend stay at the Westin Ottawa with Sunday Brunch. Raffle tickets can be turned in at various locations on the exhibit floor and the winners will be announced at the President’s Banquet on Saturday, September 9. You must be present at the banquet to win!
## Author Disclosures

<table>
<thead>
<tr>
<th>Author</th>
<th>Presentation #(#s)</th>
<th>Disclosure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adamo, Georges</td>
<td>None</td>
<td>P3, P4</td>
</tr>
<tr>
<td>Akhavan, Ardavan</td>
<td>None</td>
<td>P31</td>
</tr>
<tr>
<td>Antebi, Elie</td>
<td>None</td>
<td>P1, P5</td>
</tr>
<tr>
<td>Assimos, Dean</td>
<td>Med Rewiew in Urology, Board member or officer, Ixoion Corp., Boston Scientific, Investigator</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Badger, William</td>
<td>None</td>
<td>P22, P23</td>
</tr>
<tr>
<td>Bastian, Patrick</td>
<td>None</td>
<td>12</td>
</tr>
<tr>
<td>Belarmino, James</td>
<td>None</td>
<td>P50, P51</td>
</tr>
<tr>
<td>Benayoun, Serge</td>
<td>None</td>
<td>10, P8</td>
</tr>
<tr>
<td>Blau, Joel</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Boczko, Judd</td>
<td>None</td>
<td>28, 29, 30, P18, P19</td>
</tr>
<tr>
<td>Bojani, Naem</td>
<td>None</td>
<td>P2, P42</td>
</tr>
<tr>
<td>Brock, Gerald</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Cannon, Glenn</td>
<td>None</td>
<td>18, 36, P38</td>
</tr>
<tr>
<td>Capello, Seth</td>
<td>Astra-Zenica, Discussion of Commercial Products which involve off-label or investigational uses</td>
<td>5</td>
</tr>
<tr>
<td>Clark, Aaron</td>
<td>None</td>
<td>P62</td>
</tr>
<tr>
<td>Carroll, Peter</td>
<td>National Cancer Institute, TAP, Department of Defense, Investor, Infomedical, Meeting participant and Lecturer</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Cloutier, Vincent</td>
<td>None</td>
<td>26, P17</td>
</tr>
<tr>
<td>Conners, William</td>
<td>None</td>
<td>P39</td>
</tr>
<tr>
<td>Corcoran, Anthony</td>
<td>None</td>
<td>P25</td>
</tr>
<tr>
<td>Delongchamps, Nicolas</td>
<td>None</td>
<td>1</td>
</tr>
<tr>
<td>Elkelini, Mohamed</td>
<td>None</td>
<td>P30</td>
</tr>
<tr>
<td>Emerson, Laurel</td>
<td>None</td>
<td>P21</td>
</tr>
<tr>
<td>Eure, Gregg</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Feifer, Andrew</td>
<td>None</td>
<td>27</td>
</tr>
<tr>
<td>Ford, Beneranda</td>
<td>None</td>
<td>P46</td>
</tr>
<tr>
<td>Foster, Harris</td>
<td>Cetorelix, Board Member or officer, Boehringer Ingelheim, GSK, OrthoUrology, Consultant or advisor</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Fradet, Vincent</td>
<td>None</td>
<td>2, 23, P15</td>
</tr>
<tr>
<td>Gibbans, Erin</td>
<td>None</td>
<td>P9</td>
</tr>
<tr>
<td>Giramonti, Karla</td>
<td>Pfizer</td>
<td>22</td>
</tr>
<tr>
<td>Goldfischer, Evan</td>
<td>P1 Inc., Other</td>
<td>P37</td>
</tr>
<tr>
<td>Goldfischer, Evan</td>
<td>Astellas Pharma, Consultant</td>
<td>P43</td>
</tr>
<tr>
<td>Golijanin, Dragar</td>
<td>Novadaq Technologies Inc., Toronto, Canada, Grant Support</td>
<td>19, P52, P53</td>
</tr>
<tr>
<td>Gomella, Leonard</td>
<td>AstraZeneca, TaP, GSK, Consultant, Dendreon, Antigenics, Hexvix, Scientific study or trial</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Guru, Khurshid</td>
<td>None</td>
<td>14</td>
</tr>
<tr>
<td>Hassouna, Magdy</td>
<td>None</td>
<td>3</td>
</tr>
<tr>
<td>Jacobs, Bruce</td>
<td>None</td>
<td>P58</td>
</tr>
<tr>
<td>Jeldres, Claudio</td>
<td>None</td>
<td>P12, P13, P14</td>
</tr>
<tr>
<td>Johnston, Paul</td>
<td>None</td>
<td>P49</td>
</tr>
<tr>
<td>Karakiewicz, Pierre</td>
<td>None</td>
<td>P61</td>
</tr>
<tr>
<td>Kawashima, Hidenori</td>
<td>None</td>
<td>P41</td>
</tr>
<tr>
<td>Klotz, Laurence</td>
<td>None</td>
<td>P11</td>
</tr>
<tr>
<td>Koch, Michael</td>
<td>Focus Surgery, Investigator</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Lebeau, Thierry</td>
<td>None</td>
<td>11, 24, P59</td>
</tr>
<tr>
<td>Leveridge, Mike</td>
<td>None</td>
<td>P44</td>
</tr>
<tr>
<td>Lewinshtein, Daniel</td>
<td>None</td>
<td>13, P6, P7, P10</td>
</tr>
<tr>
<td>Lillie, David</td>
<td>None</td>
<td>6</td>
</tr>
<tr>
<td>Matoka, Derek</td>
<td>None</td>
<td>P40</td>
</tr>
<tr>
<td>Mevorach, Robert</td>
<td>None</td>
<td>P29</td>
</tr>
<tr>
<td>Menon, Mani</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Name</td>
<td>Relationship</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>--------------------------</td>
<td>---------------------------------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Moyer, Suzanne</td>
<td>None</td>
<td>15</td>
</tr>
<tr>
<td>Nakatani, Tatsuy</td>
<td>Not available at time of publication</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Mishisaka, Nobuyasu</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Nogueira, Mark</td>
<td>None</td>
<td>31</td>
</tr>
<tr>
<td>Onal, Bulent</td>
<td>None</td>
<td>21</td>
</tr>
<tr>
<td>Palapattu, Ganesh</td>
<td>None</td>
<td>P34</td>
</tr>
<tr>
<td>Patrick, Allan</td>
<td>Not available at time of publication</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Pautler, Stephen</td>
<td>None</td>
<td>P48</td>
</tr>
<tr>
<td>Pavlov-Shapiro, Sasha</td>
<td>None</td>
<td>P24</td>
</tr>
<tr>
<td>Perrotte, Paul</td>
<td>None</td>
<td>9, P55</td>
</tr>
<tr>
<td>Porter, Christopher</td>
<td>None</td>
<td>P16, P56</td>
</tr>
<tr>
<td>Ramirez, Alvaro</td>
<td>None</td>
<td>8, 25, P54</td>
</tr>
<tr>
<td>Regan, James</td>
<td>Healthtronics, Investigator</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Robb, Sylvia</td>
<td>None</td>
<td>P47</td>
</tr>
<tr>
<td>Roth, Margaret</td>
<td>None</td>
<td>33</td>
</tr>
<tr>
<td>Roth, Kirk</td>
<td>None</td>
<td>34</td>
</tr>
<tr>
<td>Shahrou, Khaled</td>
<td>None</td>
<td>4, 7</td>
</tr>
<tr>
<td>Shapiro, Oleg</td>
<td>None</td>
<td>P35, P36</td>
</tr>
<tr>
<td>Sant, Grannum</td>
<td>Vice President Urology, sanofi-aventis</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Scardino, Peter</td>
<td>Steba Pharmaceuticals, Oncovance, Inc., Merck, Sanofi-aventis, Consultant or Advisor, NCI, NIH, Prostate Cancer Foundation, Investigator, AstraZeneca, Meeting participant or Lecturer, Penquin Putnam, Inc. Book published, Nature Urology, Editor of journal</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Shah, Nikhil</td>
<td>Pfizer, Inc, Consultant or Advisor</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Shiraishi, Taizo</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Singer, Eric</td>
<td>None</td>
<td>P20, P27</td>
</tr>
<tr>
<td>Smaldone, Marc</td>
<td>None</td>
<td>16, 35, P26, P32, P33</td>
</tr>
<tr>
<td>Spana, Gregory</td>
<td>None</td>
<td>32</td>
</tr>
<tr>
<td>Stockton, Benjamin</td>
<td>None</td>
<td>37</td>
</tr>
<tr>
<td>Sugita, Shozo</td>
<td>None</td>
<td>P45</td>
</tr>
<tr>
<td>Sweeney, Danielle</td>
<td>None</td>
<td>20, P28</td>
</tr>
<tr>
<td>Uzzo, Robert</td>
<td>None</td>
<td>Guest Lecture</td>
</tr>
<tr>
<td>Wang, Ming-Hsien</td>
<td>None</td>
<td>17</td>
</tr>
<tr>
<td>Wu, Guan</td>
<td>None</td>
<td>P57, P60</td>
</tr>
</tbody>
</table>
# CME Form

Please fill out and return to the registration counter in the 4th floor Foyer at the conclusion of the conference. Only mark those courses you attend. Your CME certificates will be mailed to the address provided below.

<table>
<thead>
<tr>
<th>LAST NAME</th>
<th>FIRST NAME</th>
<th>CREDENTIALS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ADDRESS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CITY</th>
<th>STATE/PROVINCE</th>
<th>ZIP</th>
<th>COUNTRY</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Accreditation
The American Urological Association Education and Research, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The American Urological Association Education and Research, Inc. takes responsibility for the content, quality and scientific integrity of this CME activity.

## CME Credits
The American Urological Association Education and Research, Inc. designates this educational activity for a maximum of 17.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### Thursday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 9:30 a.m.</td>
<td>Live Surgery 1st Case</td>
</tr>
<tr>
<td>9:30 – 10:30 a.m.</td>
<td>Intuitive Robotic Video Session</td>
</tr>
<tr>
<td>10:30 – 11:30 a.m.</td>
<td>Live Surgery 2nd Case</td>
</tr>
<tr>
<td>1:00 – 3:00 p.m.</td>
<td>State-of-the-Art Lectures 1-4</td>
</tr>
<tr>
<td>3:30 – 5:30 p.m.</td>
<td>State-of-the-Art Lectures 5-7</td>
</tr>
</tbody>
</table>

**Thursday Total (7 possible)**

### Friday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 9:00 a.m.</td>
<td>Podium Session I – Prostate Cancer</td>
</tr>
<tr>
<td>9:00 – 9:30 a.m.</td>
<td>Guest Lecture: Lymph Node Dissection in GU Surgery</td>
</tr>
<tr>
<td>9:30 – 10:00 a.m.</td>
<td>Open vs. Robotic vs. Laparoscopic Prostatectomy (Point-Counter-Point)</td>
</tr>
<tr>
<td>9:30 – 10:30 a.m.</td>
<td>Poster Session I – Prostate Cancer</td>
</tr>
<tr>
<td>10:00 – 11:00 a.m.</td>
<td>Poster Session II – Laparoscopy, Infertility &amp; Stones</td>
</tr>
<tr>
<td>10:30 – 11:30 a.m.</td>
<td>Podium Session II – Bladder Cancer</td>
</tr>
<tr>
<td>11:30 – 12:00 p.m.</td>
<td>Guest Lecture: Superficial Bladder Cancer</td>
</tr>
<tr>
<td>1:00 – 2:00 p.m.</td>
<td>Podium Session III – Pediatrics</td>
</tr>
<tr>
<td>2:00 – 2:30 p.m.</td>
<td>Guest Lecture: Current Concepts in the Management of Posterior Urethral Valves</td>
</tr>
<tr>
<td>3:00 – 4:00 p.m.</td>
<td>Poster Session III – Pediatrics, Female Urology, Basic and General Urology</td>
</tr>
<tr>
<td>3:00 – 3:30 p.m.</td>
<td>Stump the Professor</td>
</tr>
<tr>
<td>3:30 – 4:00 p.m.</td>
<td>Podium Session IV – Prostate Cancer Recurrence/Biopsies</td>
</tr>
<tr>
<td>4:00 – 4:30 p.m.</td>
<td>Guest Lecture: Prostate Cancer</td>
</tr>
</tbody>
</table>

**Friday Total (7.25 possible)**

### Saturday

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 – 9:00 a.m.</td>
<td>Podium Session V – Laparoscopy</td>
</tr>
<tr>
<td>9:00 – 10:00 a.m.</td>
<td>Poster Session IV – Other Cancer</td>
</tr>
<tr>
<td>9:00 – 9:30 a.m.</td>
<td>Slotkin Lecture</td>
</tr>
<tr>
<td>10:00 – 10:30 a.m.</td>
<td>Podium Session VI – Stones</td>
</tr>
<tr>
<td>10:30 – 11:00 a.m.</td>
<td>Guest Lecture: Surgical Management of Patients with Complex Nephrolithiasis</td>
</tr>
<tr>
<td>11:00 – 11:30 a.m.</td>
<td>Guest Lecture: Interstitial Cystitis – Update on Pathophysiology and Treatment</td>
</tr>
</tbody>
</table>

**Saturday Total (3.5 possible)**

**OVERALL TOTAL HOURS (Total Possible Hours 17.75)**